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ABSTRACT OF THE DISSERTATION
Novel Role of CHK2 in the Intrinsic and Extrinsic Apoptosis Pathway
by
Anurag Agarwal
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in Saint Louis, 2014
Professor Helen Piwnica-Worms, Chair

In response to genotoxic stress, cells activate DNA damage checkpoint pathways that
maintain genetic fidelity, promote cell survival, and prevent malignant transformation.
Checkpoint kinase 2 (CHK2) is an evolutionarily conserved serine/threonine protein
kinase that is activated in response to DNA double strand breaks. Upon activation by
the DNA damage transducer kinase, ATM, CHK2 phosphorylates a wide variety of down
stream effectors to promote cell cycle arrest, DNA repair and apoptosis. One of they key
downstream substrate of CHK2 is the tumor suppressor protein, p53. CHK2 is
considered as a key kinase in DNA damage-induced p53 regulation and thought to
mediate most of its downstream effects through p53.
This dissertation has further strengthened the growing pool of evidence that
CHK2 is dispensable for p53 regulation but rather signals to the apoptotic machinery
through effector proteins other than p53. I have identified cellular Inhibitor of Apoptosis
proteins (cIAPs) as novel CHK2 targets and established their role in CHK2-mediated
cell death. In response to DNA damage, CHK2 inhibits both cIAP1 and cIAP2 to relieve

ix

their anti-apoptotic effects and drive cells into apoptosis. CHK2 inhibits the E3 ubiquitin
ligase activity of cIAP2 in a phosphorylation dependent manner and potentially
regulates cIAP1 through its interaction with cIAP2. Furthermore, this work provides
preliminary evidence that CHK2 serves as a negative regulator of the NFκB pathway
through the inhibition of cIAPs. Upon activation, CHK2 potentiates TNFα Related
Apoptosis Inducing Ligand (TRAIL)-induced apoptosis through the regulation of the
NFκB pathway.
Overall, my work has discovered a novel role of CHK2 in the DNA damage
induced intrinsic apoptotic pathway and uncovered its potential role in death receptor
mediated extrinsic apoptotic pathway.
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Chapter 1:
Introduction
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1.1 Genomic Instability and DNA Damage Response Pathway
Numerous internal and environmental factors pose a constant threat to the genetic
information within a cell. These factors include replication fidelity, collapse of replication
forks, and reactive oxygen species, and external factors, like ionizing radiation (IR),
ultraviolet radiation (UV), and genotoxic chemicals. In order to maintain genomic
integrity, cells have developed a complex array of signaling pathways, known as the
DNA damage response (DDR) pathway, to sense DNA damage and execute specific
cellular responses like cell cycle arrest, i.e. senescence, DNA damage repair and/or cell
death. Defects in DDR can render the genome unstable and drive malignant
transformation through accumulation of various genetic alterations. For this reason,
Hanahan and Weinberg have proposed genomic instability as the most prominent
enabling characteristic of tumorogenesis in their seminal description of the hallmarks of
cancer (Hanahan and Weinberg et. al., 2011). Therefore, careful understanding of the
DDR pathway has provided key insight into the process of transformation and cancer
development.
The DDR pathway can be divided into three tiers: sensors, transducers and
effectors. DDR sensors identify the lesion and with the help of mediators and activate
the transducers to begin the DDR signaling cascade. Transducers amplify the DNA
damage signal from the sensors and activate the effector molecules to execute the
appropriate cellular response.
DNA Single Strand Breaks (SSBs) and Double Strand Breaks (DSBs) are two major
forms of DNA damage that elicit a DDR response. DNA DSBs are formed in response to
either various stimuli like IR or treatment with topoisomerase II inhibitors (VP16 and
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doxorubicin) that prevent re-ligation of the DNA strands broken by topoisomerase II.
DNA DSBs can also be formed by replicating DNA with specific lesions like DNA single
strand breaks (SSBs) or by nucleases in V(D)J and class switch recombination. On the
other hand, DNA SSBs are formed in response to treatment with UV, hydroxyurea (HU),
DNA alkylating agents, or other chemicals that stall the replication fork. Distinct DDR
pathways are activated in response to different forms of DNA damage. While the ATMCHK2-p53 axis controls the cellular response to DNA DSBs, the ATR-CHK1-Cdc25A
axis mediates the effect of DNA SSBs (Smith et al. 2010). Although distinct pathways
are activated initially in response to different forms of DNA damage, over a period of
time, one form of damage is converted into another form, which leads to the activation
of both DDR responses. For example, repair of DNA DSBs requires processing of the
DNA ends. As a result, single stranded DNA is exposed and activates the SSB
response. Similarly, SSBs are converted into the DSBs during replication. In the next
section, I will introduce the cellular response to DNA DSBs in more detail and discuss
the signaling cascade that eventually leads to activation of the checkpoint kinase,
CHK2. Table 1 summarizes the different components of the DDR response to different
forms of DNA damage.
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DNA DSBs

DNA SSBs

Sensors

Mre11, Rad50, Nbs1

RPA

Mediators

MDC1, BRCA1, 53BP1, H2AX ATRIP, Claspin, TopBP1, 9-1-1, Rad17

Transducers ATM

ATR

Effectors

p53, Cdc25A

CHK2, p53, E2F1, MDMX

Table 1. List of proteins involved in the DDR pathway in response to DNA DSB and
SSBs.
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1.2 DNA Double Strand Breaks
DNA DSBs are one of the most detrimental forms of DNA damage as a double strand
break does not leave behind a complementary strand to recover the lost information.
Furthermore, DSBs are pre-requisites for chromosomal rearrangements, especially
translocations, which are associated with various malignancies (Mitelman et al., 1997;
Rabbitts, 1994). One the one hand, chromosomal translocations can produce a fusion
protein composed of two truncated proteins with the fusion protein acquiring unique or
altered activity. On the other hand, chromosomal translocations can result in
transferring a whole gene downstream to a different regulatory element resulting in
altered expression of the native protein.
In 1961 Nowell and Hungerford discovered the first chromosomal translocation,
known as Philadelphia Chromosome, in chronic myelogenous leukemia (Nowell, 2007).
This translocation results in the fusion of BCR and ABL1 gene. Abl1 is a tyrosine kinase
whose activity is tightly regulated on the plasma membrane. The fusion protein disrupts
the native regulation and converts Abl1 into a constitutively active kinase (Ben-Neriah et
al., 1986; Van Etten et al., 1989). Soon after, translocation between chromosome 8 and
14 was discovered in Burkitt’s lymphoma (Zech et al., 1976) where c-MYC gene is
juxtaposed to the immunoglobulin heavy-chain genes and results in over-expression of
MYC (Deshmukh et al., 1982; Taub et al., 1982). While chromosomal translocations are
highly prevalent in the hematological malignancies, translocations have also been
implicated in the development of several epithelial and mesenchymal malignancies as
well (Rowley, 2001). Therefore, in order to prevent detrimental effects of unresolved
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DSBs, cells have developed a sensitive response pathway that detects and resolves
such breaks.

1.3 DNA Double Strand Break Sensors
The Mre11-Rad50-Nbs1 (MRN) protein complex serves as the sensor of DNA DSBs.
MRN complex rapidly moves to the damage sites and forms a bridge spanning the two
edges of the break. Mre11 possesses intrinsic DNA binding property to synapse the
DSB termini (Williams et al., 2008). Additionally, exonuclease and endonuclease
properties of Mre11 are critical for Non homologous end joining (NHEJ)- and HRmediated repair of damaged ends (de Jager et al., 2001a; Paull and Gellert, 1998,
1999). Mre11 interacts with Rad50 and recruits it to damage sites. This strengthens the
interaction of the complex with the broken ends of the DNA. Rad50 is also capable to
mediating long distance interactions like those with sister chromatids (de Jager et al.,
2001b; Lamarche et al. 2010). Nbs1, the third component of the MRN complex, contains
the FHA and BRCT domains that mediate protein-protein interactions and is critical in
recruiting other proteins to the damage site (Lloyd et al., 2009; Williams et al., 2009).
Moreover, the nuclear localization signal in Nbs1 keeps the MRN complex in the
nucleus (Desai-Mehta et al., 2001).
Defects in MRN complex results in dampened DDR to DSBs and predispose
cells to malignant transformation. Hypomorphic mutations in Mre11, Rad50 and Nbs1
results in neurological disorders such as ataxia-telangiectasia like disorder (ATLD),
Nijmegen breakage syndrome (NBS) and NBS like disorder (NBSLD) (Carney et al.,
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1998; Kobayashi et al., 2004; Taylor et al., 2004; Waltes et al., 2009). This underscores
the importance of the MRN complex, as well as DDR, in the nervous system.

1.4 Transducer Kinase: ATM
One of the central roles of MRN complex in DDR is the recruitment and activation of the
transducer kinase, ataxia-telangiectasia mutated (ATM). Analysis of ataxiatelangiectasia (AT) patients, who are characterized by cerebral ataxia, immunological
dysfunction, sensitivity to ionizing radiation and cancer pre-disposition, gave the first
insight into the role of ATM in DNA DSBs. ATM is a serine/threonine protein kinase that
belongs to the family of PI3K-like protein kinases (PIKK). ATR and DNA-PK are other
two PIKKs that are also involved in the DDR pathway. While ATR is activated in
response to SSB (Nam and Cortez), DNA-PK is primarily known for its role in NHEJmediated DNA repair (Hill and Lee; Neal and Meek). On the other hand, ATM is
preferentially activated by DNA DSBs and plays a central role in cellular response to
DSBs. Under normal conditions, ATM exists as an inactive homodimer. Upon DSBs,
ATM is rapidly recruited to the DNA DSBs through its interaction with Nbs1, (You et al.,
2005) where it undergoes intermolecular phosphorylation at the conserved residue,
serine 1981, to transform itself into an active monomer (Bakkenist and Kastan, 2003). In
addition to S1981, three other autophosphorylation sites, as well as acetylation of lysine
3016, regulates the kinase activity of ATM (Kozlov et al.; Kozlov et al., 2006; Sun et al.,
2005; Sun et al., 2007). Although these modifications facilitate ATM activation, ATM
activity is fine tuned by other DDR pathway proteins like MDC1, BRCA1, 53BP1 and
MRN complex (Cerosaletti and Concannon, 2004; Lee and Paull, 2004, 2005). Among
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these mediators of the DDR pathway, it is noteworthy to discuss the interaction between
ATM and MDC1. MDC1 is required for timely activation of ATM and plays a key role in
expanding the DNA damage signal around the damage sites. ATM phosphorylates the
histone variant H2AX at serine 139, to generate γH2AX (Burma et al., 2001), which is
widely used as a marker for DSBs. MDC1 is tethered to the chromatin through its
interaction with γH2AX and in parallel binds to ATM (Stucki et al., 2005). This allows
ATM to phosphorylate more H2AX molecules resulting in expansion of the DNA
damage signal around the sites of damage. Similarly, ATM phosphorylates Nbs1 to form
a positive feedback loop that keeps ATM activation for prolonged periods of time (Gatei
et al., 2000; Zhao et al., 2000).
Upon activation, ATM phosphorylates numerous effector proteins to mediate
various cellular responses like cell cycle arrest, DNA repair and/or apoptosis. Like other
PIKK family members, ATM preferentially phosphorylates the serine or threonine
residues that precede glutamine residue (SQ/TQ) (Kastan and Lim, 2000; Kim et al.,
1999; O'Neill et al., 2000). Among various downstream effectors of ATM, I will focus on
three specific proteins – p53, CHK2 and NFκB.
One of the first well-characterized targets of ATM was p53. p53 is a transcription
factor that is most commonly mutated in cancers and contributes to the development of
more than half of all human cancers. p53 regulates a wide variety of cellular functions
like cell cycle arrest, apoptosis, DNA repair, autophagy and many more (Choi et al.;
Rashi-Elkeles et al.; Sullivan et al.). The first evidence of ATM-mediated regulation of
p53 came from the observation that p53 levels were dysregulated in cells lacking ATM
(Canman et al., 1994; Siliciano et al., 1997). It was later found that ATM phosphorylates
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p53 on Ser-15 that promotes its interaction with another transcription factor, p300,
which is essential for transcriptional activity of p53 (Banin et al., 1998; Canman et al.,
1998; Dumaz and Meek, 1999). Moreover, ATM phosphorylates and inhibits MDM2 and
MDMX to promote p53 stabilization in response to DSBs (Chen et al., 2005; Cheng et
al., 2009; Cheng et al.; Khosravi et al., 1999; Maya et al., 2001). ATM is also able to
regulate p53 through activation of CHK2 (discussed later in section 1.5.2). Another key
downstream effector of ATM is NFκB. NFκB is a transcription factor that is sequestered
in the nucleus by IκBα. In response to various stimuli, including DNA damage
(Miyamoto), an upstream kinase IKK phosphorylates IκBα and targets it for proteosomal
degradation (Perkins, 2007; Piret et al., 1999; Wu et al., 2006). As a result the NFκB
transcription factor moves into the nucleus and transcribes a wide variety of genes that
support cell survival. ATM is believed to play a key role in NFκB activation in response
to DNA damage by phosphorylating the regulatory subunit of IKK, NEMO (Piret et al.,
1999; Wu et al., 2006; Wu et al.; Yang et al.). ATM has also been shown to regulate the
NFκB pathway independent of its effect on NEMO (Wu et al.; Yang et al.). Overall, ATM
plays a central role in mediating the DDR to DSBs through amplification of DNA
damage signaling and transmitting the signal downstream to effector proteins.

1.5 Effector Kinase: CHK2
CHK2 is a serine/threonine protein kinase that is activated in response to DNA DSBs in
an ATM-dependent manner. CHK2 serves as a tumor suppressor by inducing cell cycle
arrest or apoptosis in cells with DNA damage. Heterozygous germline mutations in
CHK2 are associated with a p53-independent variant form of the Li-Fraumeni syndrome
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(Bell et al., 1999). Additionally, CHK2 mutations are also found in sporadic cancers
(Dong et al., 2003; Schutte et al., 2003; Sodha et al., 2002) and down regulation of
CHK2 protein has been reported in several cancers (Bartkova et al., 2004; Sullivan et
al., 2002; Tort et al., 2002). The role of CHK2 mutations in different forms of familial and
sporadic cancers will be discussed in detail later (Section 1.6).

1.5.1 CHK2: Structure
The CHK2 gene on chromosome 22 (22q12.1) encodes a 68kD protein that consists of
three distinct functional domains; an SQ/TQ cluster domain (SCD, residues 19 - 69), a
forkhead-association (FHA) domain (112- 175), and a Ser/Thr kinase domain (residues
220 – 486). The SCD contains five serine (S19, S27, S33, S35, and S50) and two
threonine (T36, and T68) residues that precede a glautamine (Q). Serine or threonine
residues followed by glutamine (SQ/TQ) provides a substrate recognition motif that is
phosphorylated by ATM in response to DNA damage. Moreover, residues surrounding
Thr68, S-T68-Q-E (residues 67 – 70) closely resemble the refined substrate motif
(LSQE) of ATM (O'Neill et al., 2000). ATM phopshorylates CHK2 at T68 to initiate its
activation (Ahn et al., 2000a). In addition to T68, other SQ/TQ sites have been shown to
be phosphorylated by ATM (Matsuoka, 1998; Matsuoka et al., 2000). Downstream of
SCD is the FHA domain that works primarily in trans to modulate protein-protein
interactions. The FHA domain can also work in cis to affect other functional domains
within a protein (Ahn et al., 2004). FHA domains are 65 – 100 amino acid long
phosphopeptide binding domains that were first identified in a family of forkhead
transcription factors (Hofmann and Bucher, 1995). The FHA domain of Rad53, a CHK2
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homolog in Saccharomyces cerevisiae, is essential for its interaction with Rad9 (human
homolog of Rad9 remains to be identified) (Sun et al., 1998b). Both, biochemical
analysis and the crystal structure of the FHA domain of CHK2 indicate that the FHA
domain is crucial for CHK2 dimerization and activation in response to DNA damage (Cai
et al., 2009; Schwarz et al., 2003a; Sun et al., 1998a). The C-terminus of CHK2 is
occupied by the kinase domain. It is characterized by a glycine rich region at the vicinity
of lysine residue in the N-terminal and an aspartic acid as a catalytic residue in the
active site. Like other kinases, the activation loop prevents ATP binding and keeps the
kinase in an inactive conformation. Upon phosphorylation, the activation loop is
displaced from the catalytic center to activate kinase activity (Oliver et al., 2006).

1.5.2 CHK2: Activation
CHK2 remains in an inactive state throughout the mammalian cell cycle (Lukas et al.,
2001). However, upon DNA damage, CHK2 is rapidly phosphorylated and activated in
an ATM-dependent manner (Figure 1). Like ATM, CHK2 is preferentially activated in
response to DNA DSBs which are caused by IR, chemotherapeutic agents like
etoposide (VP16) and doxorubicin. Upon DNA DSBs, ATM phosphorylates CHK2 at
Thr68 within the SCD, a key step in CHK2 activation. There are several key lines of
evidence that underscore a role for ATM in phosphorylating CHK2. First, CHK2
activation and phosphorylation at Thr68 is abrogated in cells lacking ATM. However,
CHK2 activation can be restored through exogenous expression of WT ATM (Brown et
al., 1999; Chaturvedi et al., 1999; Matsuoka, 1998). IR-mediated CHK2 activation is
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impaired in cell lines derived from AT patients that lack functional ATM (Zhou et al.,
2000). Furthermore, ATM directly phosphorylates CHK2 in vitro at several sites
including Thr68 (Ahn et al., 2000b; Matsuoka et al., 2000; Melchionna et al., 2000). In
addition to ATM, DNA-PK, one of the PIKK family members, and PLK1 are also able to
phosphorylate CHK2 at Thr68 in vitro (Li and Stern, 2005; Tsvetkov et al., 2003).
Phosphorylation of Thr68 plays a key role in CHK2 activation by promoting
oligomerization-induced auto- and trans-phosphorylation. In fact, complete activation of
CHK2 requires cis- and trans-phosphorylation of several residues, including Thr383 and
Thr387 within the activation loop (Schwarz et al., 2003b). In the model proposed by
Schwarz et. al. (2003), a molecule of CHK2 phosphorylated at Thr-68 binds to the FHA
domain of another CHK2 molecule. Such dimerization drives several autophosphorylation events that are required for CHK2 activation (Schwarz et al., 2003b).
This model is supported by numerous independent studies. First, substituting alanine for
threonine at residue 68 abolishes the interaction of CHK2 with recombinant FHA
domain of CHK2 and impairs CHK2 activation. (Ahn et al., 2002; Li et al., 2002).
Additionally, mutation of FHA domain that affects oligomerization impairs the ability of
CHK2 to be activated after DNA damage (Cai et al., 2009; Oliver et al., 2006).
Furthermore, forced dimerization of CHK2 is sufficient to activate its kinase activity.
Overproduction of CHK2 in HEK293 cells or bacteria can induce CHK2 dimerization,
Thr68 phosphorylation, and activation in the absence of DNA damage (Schwarz et al.,
2003b; Xu et al., 2002). Additionally, CHK2 can be forced to oligomerize, and become
activated, by the addition of a modified FKBP epitope and a synthetic ligand. Forced
oligomerization of CHK2 also results in the phosphorylation of Thr68 (Xu et al., 2002).
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This suggests that, in addition to ATM, CHK2 can auto-phosphorylate Thr68 and drive
its own activation. In addition to interaction with other CHK2 molecules, CHK2
phosphorylation on Thr68 mediates CHK2 interaction with another DDR pathway
protein, MDC1. The FHA domain of MDC1 interacts with Thr68 phosphorylated CHK2
both in vitro and in vivo (Lou et al., 2003). This interaction is critical for DNA repair and
apoptosis in cells with DNA DSBs.
As discussed above, oligomerization-induced autophosphorylation of CHK2 is
essential for its activation. Among numerous auto-phosphorylation sites, Thr383 and
Thr387 are most critical to CHK2 kinase activity. Thr383 and Thr387 are present in the
activation loop and mutation of these residues to alanine abrogates CHK2 activity. (Lee
and Chung, 2001). The a ctivation loop is a 20 – 30 amino acid long protein segment
that blocks substrate access to the ATP binding pocket of protein kinases (Hanks and
Hunter, 1995). Upon phosphorylation, the activation loop is tethered away from the ATP
pocket allowing substrate access and transfer of the phosphate. Similarly,
phosphorylation of Thr383 and Thr387 within the activation loop opens the active site of
CHK2 and allows it to phosphorylate its substrates.
CHK2 has also been shown to interact with two different phosphatases, PP2A
and Wip1 that dephosphorylate CHK2 on various residues. A yeast two-hybrid screen
identified the B’ regulatory subunit of PP2A as a CHK2 partner. PP2A was capable of
dephosphorylating CHK2 in vitro and countered adramycin-induced CHK2 activation
(Dozier et al., 2004). Two separate groups demonstrated that Wip1 can
dephosphorylate CHK2 at Thr68 and antagonize its downstream function (Fujimoto et
al., 2005; Oliva-Trastoy et al., 2007). Fujimoto et. al. 2005 found that CHK2 associates
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with Wip1 both in vitro and in vivo. Moreover, Wip1 is able to dephosphorylate CHK2 on
Ser19, Ser33/35, Thr68, and Thr432 but not on Thr387 or Ser516. Furthermore,
overexpression of Wip1 inhibits Thr68 phosphorylation in vivo. On the other hand, OlivaTrastoy et. al. 2007 demonstrated that overexpression of Wip1 in HCT15 cells
abrogates CHK2-mediated G2 arrest in response to IR.

1.5.3 CHK2: Regulation
Upon oligomerization, CHK2 can auto-and trans phosphorylate on several serine and
threonine residues. Thus, various studies have focused on identifying these
phosphorylation sites and their role in CHK2 function (Kass et al., 2007; King et al.,
2007; King et al., 2006). In this section, I will introduce how CHK2 auto/transphosphorylation sites regulate CHK2 ubiquitination. Ubiquitin is a small protein that is
covalently attached to proteins through E3 ligases. Ubiquitination of proteins can target
them for proteosomal degradation or alter their activity and downstream signaling.
Cellular protein levels are tightly regulated through a balance between ubiquitination by
E3 ligases and deubiquitination by deubiquitining enzymes. In mammalian cells, CHK2
is a stable protein and is expressed throughout the cell cycle. However, low levels of
CHK2 are observed in a subset of breast cancer (Sullivan et al., 2002; Vahteristo et al.,
2002), testicular cancer (Bartkova et al., 2001) and lymphomas (Tort et al., 2002). First
evidence of post-translational modification of CHK2 other than phosphorylation came
from the study by Lovly et. al. (2008). This study identified Ser379 phosphorylation as a
positive regulator of CHK2 ubiquitination (Lovly et al., 2008). Ectopically expressed wildtype CHK2, but not the S37A mutant of CHK2, underwent ubiquitination in HEK293
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cells. Interestingly, this ubiquitination did not alter CHK2 turnover in the cells but rather
contributed to the apoptotic pathway downstream of CHK2 (Lovly et al., 2008).
Ubiquitination of CHK2 is balanced by deubiquitinating enzyme USP28. USP28
promotes CHK2 stabilization (Zhang et al., 2006) and is also found in the same complex
as CHK2 and Pirh2. Overall, several proteins have been shown to regulate CHK2 levels
in response to DNA damage; however, further studies would be needed to understand
the physiological role of such regulation and if these pathways are dysregulated in
certain cancers.

1.5.4 CHK2: Downstream Effectors
CHK2 plays a central role in cellular response to DNA DSBs. Once activated, CHK2
phosphorylates a wide-variety of substrates, which in turn regulate cell cycle arrest,
DNA repair and apoptosis (Figure 2). In this section, I will introduce various downstream
effectors of CHK2 and their effects on cells with DNA damage.

BRCA1
BRCA1 has been shown to be a CHK2 substrate. It plays multiple roles in the DDR
pathway, including activation of the intra-S and G2/M cell cycle checkpoints, DNA
repair through homologous recombination (HR) NHEJ and modulating transcription of
DNA damage responsive genes, 14-3-3σ and GADD45 (Ting and Lee, 2004). BRCA1
mutations pre-dispose patients to breast and ovarian cancers. In response to DNA
damage, BRCA1 is hyper-phosphorylated by various DDR kinases including ATM
(Cortez et al., 1999) and CHK2 (Lee et al., 2000). BRCA1 contains a CHK2 consensus
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phosphorylation motif (L X R X X S/T) (O'Neill et al., 2002) and is phosphorylated at
Ser988. Studies have reported that unlike the wild type protein, expression of the
S988A mutant in BRCA1 deficient cells fails to increase survival and restore HR (Zhang
et al., 2004a). Similarly overexpression of kinase-dead CHK2 (acts as a dominant
negative mutant), blocks Ser988 phosphorylation of BRCA1 and abolishes DSB repair
in response to IR. In addition to HR, Ser988 phosphorylation of BRCA1 is critical for
error-free NHEJ in response to DNA damage (Zhuang et al., 2006).

E2F-1
In response to VP16, CHK2 has been reported to phosphorylate E2F-1 at Ser364, a
CHK2 consensus motif (L X R X X S). E2F-1 is a member of E2F family of transcription
factors that play a key role in G1- to S- cell cycle transition. E2F-1 activity is regulated
during cell cycle through association with the tumor suppressor protein, retinoblastoma
(Rb) (Flemington et al., 1993; Helin et al., 1993). Under normal conditions, cyclin
D/cdk4, 6 (G1 phase) and cyclin E/cdk2 (S phase) hyperphosphorylate Rb, which
results in the dissociation of E2F-1/Rb complex (Knudsen and Wang, 1997). In turn,
E2F-1 promotes the transcription of various genes critical for cell cycle progression. The
ability of E2F-1 to induce apoptosis in response to DNA damage differentiates it from
other members of the E2F family. E2F-1 is best known for targeting the promoters of the
pro-apoptotic genes, p73 and Arf (Bates et al., 1998; Irwin et al., 2000). CHK2 has been
reported to phosphorylate E2F-1 in vitro at Ser364. Phosphorylation of E2F-1 at Ser264
stabilizes the E2F-1 protein by increasing its half-life (Stevens et al., 2003) and localizes
the phosphorylated protein to DNA damage sites. Overexpression of dominant negative
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CHK2 can prevent E2F-1 induced apoptosis in U2OS cells. Furthermore, CHK2, as well
as CHK1, stabilize E2F-1 to drive p73 expression and induce p53-independent
apoptosis in cells with DNA damage (Urist et al., 2004). Interestingly, E2F-1 has been
shown to induce ATM-mediated phosphorylation of CHK2 at Thr68, suggesting a
potential positive feedback loop (Powers et al., 2004).

PML
Another pro-apoptotic substrate of CHK2 is PML. PML is a tumor suppressor protein
that is translocated in most promyelocytic leukemias. PML nuclear bodies are dynamic
sensors of DNA damage and their numbers rapidly increase in response to DNA DSBs.
PML has been shown to play a role in multiple apoptotic pathways, including in
response to DNA damage (Quignon et al., 1998; Wang et al., 1998). Yang et. al. (2002)
reported that CHK2 co-localizes at nuclear foci and co-immunoprecipitates with PML in
non-irradiated cells. After IR, CHK2 phosphorylates PML at Ser117, which in turn,
promotes the dissociation of CHK2 and PML (Yang et al., 2002). Mutation of Ser117 to
Alanine impairs IR-induced apoptosis indicating a critical role of Ser117 phosphorylation
in PML-induced apoptosis. Furthermore, it has been suggested that PML forms the
scaffold protein for CHK2 and p53 and all the three proteins co-localize to nuclear
bodies. Moreover, like CHK2 null MEFs (Hirao et al., 2002; Hirao et al., 2000; Takai et
al., 2002), PML null MEFs fail to stabilize p53, phosphorylate p53 at Ser20 and induce
apoptosis in response to IR (Louria-Hayon et al., 2003).

Che-1
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CHK2 and ATM have both been shown to interact with, phosphorylate and promote the
accumulation of Che-1 in response to DNA damage (Bruno et al., 2006). Che-1 is a
highly conserved RNA polymerase II (pol II) binding protein that is important for normal
gene transcription and cell proliferation (Bruno et al., 2002; Fanciulli et al., 2000;
Lindfors et al., 2000). In response to DNA damage, Che-1 is phosphorylated on multiple
sites resulting in its accumulation. Che-1 stabilization is reduced in cells lacking
functional CHK2 and can be restored with reconstituted wild-type but not kinase-dead
CHK2. Furthermore, accumulated Che-1 is recruited to the TP53 promoter resulting in
upregulation of p53 expression, suggesting another mechanism by which ATM and
CHK2 kinases regulate p53-dependent apoptosis in response to DNA damage (Bruno
et al., 2006).

FoxM1
FoxM1 is a member of Forkhead family of transcription factors that share a common
winged helix DNA binding domain (Clark et al., 1993). FoxM1 is involved in regulating
the expression of cell cycle genes that are crucial for progression through DNA
replication and mitosis (Wang et al., 2005; Wang et al., 2002). CHK2 has been reported
to phosphorylate FoxM1 on Ser361, which results in stabilization of the FoxM1 protein.
In turn, FoxM1 transcribes XRCC and BRCA2 genes that are involved in DNA repair.
These finidings provides additional insight into how CHK2 might regulate DNA repair in
cells with DNA damage.

Survivin
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Survivin is the smallest member of Inhibitor of Apoptosis protein (IAP) family, which
have the characteristic N-terminal Zn2+-binding baculoviral IAP repeat (BIR) domain.
Survivin is primarily known for its role in mitosis and apoptosis. Survivin is a part of the
chromosomal passenger complex and is required for activation of Aurora Kinase B in
mitosis (Bolton et al., 2002; Kelly et al.). Survivin also regulates apoptosis by
cooperating with XIAP and interfering with caspase-3 and caspase-9 (Shin et al., 2001;
Tamm et al., 1998). Unlike other members of the IAP family, survivin is expressed in a
variety of neoplasms but not in differentiated tissues. Moreover, its expression is
associated with poor prognosis in oral, breast and colorectal cancer patients (Altieri,
2008a, b; Kanwar et al.). Ghosh et. al. (2006) showed that following DNA damage,
survivin is released from the mitochondria in a CHK2-dependent manner to exert its
anti-apoptotic effect. This is in contrast to the general belief that CHK2 primarily plays a
pro-apoptotic role. Overexpression of kinase-dead CHK2, or knockdown of CHK2 using
siRNA, prevented release of Survivin from mitochondria and increased apoptosis in
response to DNA damage (Ghosh et al., 2006). The same group went further to show
that CHK2 phosphorylates multiple residues of a splice variant form of Survivin, Survivin
ΔEx3 (Lopergolo et al.). Through bioinformatic analysis, Lopergolo et. al. 2012 showed
that Survivin ΔEx3 is associated with aggressive cancer and is primarily localized to the
nucleus where it becomes a CHK2 substrate. Mutation of CHK2 target sites on survivin
(Thr79, Ser98, and Thr127) to alanine enhanced Survivin ΔEx3 ability, abrogated DNA
sensing, reducing the appearance of γH2AX (marker for DNA DSBs) and impaired longterm clonogenic tumor cell survival. In summary, these studies show that CHK2
positively regulates Survivin to promote cell survival to drive tumorogenesis.

19

p53, MDM2 and MDMX
One of the most important and widely studied substrate of CHK2 is p53. p53 is a
transcription factor that has been coined the “guardian of the genome” as it is
responsible for maintaining genomic stability (Lane, 1992a, b). It is mutated in more
than half-of all human cancers with more than 18,000 characterized mutations (Olivier
et al., 2004). Under unstressed conditions, p53 is expressed at low levels and has a
very short half-life. It is rapidly targeted for ubiquitin-mediated proteosomal degradation
by its E3 ligase Mdm2 (Honda et al., 1997; Kastan et al., 1991; Momand et al., 1992). In
response to DNA damage, p53 dissociates from MDM2 and accumulates within the cell.
In turn, p53 tertramerizes and induces transcription of various genes involved in cell
cycle arrest (p21 (el-Deiry et al., 1993; Harper et al., 1993), 14-3-3σ (Hermeking et al.,
1997)), and apoptosis (BAX (Miyashita and Reed, 1995; Reed et al., 1998), PUMA (Yu
et al., 2001a), NOXA (Oda et al., 2000)). Additionally, p53 also transcribes its own
negative-regulator, MDM2 (Barak et al., 1994; Barak et al., 1993).
The relation between p53 and CHK2 is complex. Traditionally it was believed that
CHK2 is the sole kinase responsible for phosphorylating p53 on Ser20. Phosphorylation
of p53 on Ser20 disrupts its interaction with MDM2, which in turn, results in p53
accumulation and cell cycle arrest and apoptosis (Chehab et al., 2000; Chehab et al.,
1999; Hirao et al., 2000). CHK2 was shown to phosphorylate p53 in vitro Ser15, Thr18,
Ser20 and Ser37 (Shieh et al., 2000). Analysis of various deletion mutants of p53
revealed that CHK2 was only able to phosphorylate the terameric form of p53, and not
the monomeric form, at Ser15 and Ser20. Ectopic expression of dominant negative
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CHK2 abrogated p53 stabilization and Ser20 phosphorylation in IR-treated U2OS cells.
Conversely, overexpression of CHK2 induced p53 stabilization and G1 cell cycle arrest
(Chehab et al., 2000).
Analysis of two different CHK2 null mouse lines further strengthened the role of
CHK2 in p53 phosphorylation. First, Hirao et. al. (2000) showed the CD4+ and CD8+
thymocytes, developing neurons and hair follicular cells isolated from CHK2 null mice
were unable to undergo apoptosis in response to whole body IR and these mice
developed tumors more rapidly when compared to CHK2 wild-type mice (Hirao et al.,
2002). More importantly, IR-induced p53 stabilization and activation of its target genes,
p21 and BAX, were impaired in thymocytes isolated from CHK2 null mice. Similar
observations were made in a CHK2 null MEFs (Hirao et al., 2000; Jack et al., 2002).
p53 stabilization and Ser20 phosphorylation were rescued by reintroduction of wild-type
CHK2 and completely abrogated by introduction of dominant negative p53. This
provided further support that CHK2 acts upstream of p53 to phosphoryate it at Ser20
and regulate its stabilization in response to DNA damage.
Takai et. al. (2002) generated another line of CHK2 null mice and showed that
multiple tissues of these mice were more resistant to the IR-induced apoptosis and
failed to induce G1 cell cycle arrest. This is consistent with the role of CHK2 in p53mediated apoptosis and cell cycle arrest (Takai et al., 2002). However, Takai and
colleagues observed a 30 – 50% reduction in p53 levels in CHK2 null MEFs compared
to wild-type control MEFs. Interestingly, despite marginal reduction in p53 accumulation,
absence of CHK2 completely abolished p53-mediated transcription of p21, BAX, NOXA,
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Cyclin G1 and MDM2. Absence of transcriptional activity of p53 would explain the
defects in apoptosis and cell cycle arrest observed in CHK2 null mouse.
In addition to regulating p53 directly, CHK2 has also been shown to regulate p53
through the regulation of MDMX. MDMX is a MDM2 homolog that is capable of binding
p53 and inhibiting its transcriptional activation (Shvarts et al., 1996). Unlike MDM2,
MDMX cannot directly ubiquitinate and degrade p53 (Stad et al., 2001), but rather
coordinates with MDM2 to promote p53 destruction (Gu et al., 2002). The role of MDMX
in p53 regulation is further supported by the fact that the embryonic lethality of MDMX
null mice is rescued by p53 loss (Migliorini et al., 2002; Parant et al., 2001). CHK2 has
been shown to phosphorylate MDMX at Ser342 and Ser367 in vitro and in vivo (Chen et
al., 2005; Pereg et al., 2006). Mutation of Ser367 to alanine was sufficient in stabilizing
MDMX and reducing its ubiquitination. Numerous studies have shown that MDM2 can
induce MDMX degradation in response to DNA damage (de Graaf et al., 2003; Kawai et
al., 2003; Pan and Chen, 2003). MDMX degradation was significantly reduced in CHK2
null HCT116 cells further supporting a role for CHK2 in MDMX degradation. However, in
both parental and CHK2 null HCT116 cells, MDM2 was successful in degrading
ectopically expressed MDMX. Taken together this suggests that CHK2 can facilitate
MDMX degradation, and thereby, promote p53 accumulation and its downstream
function (Okamoto et al., 2005). However, it still remains unknown how CHK2
phosphorylation increases association between MDM2 and MDMX. A couple of recent
studies have indicated that Ser367 phosphorylation of MDM2 creates a 14-3-3 binding
site and can result in nuclear translocation of MDMX where it associates with MDM2
(LeBron et al., 2006). On the other hand, 14-3-3 binding might displace the
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deubiquitinating enzyme, HAUSP, and promote degradation of MDMX (Meulmeester et
al., 2005).
It has been recently challenged that CHK2 is the sole kinase responsible for p53
accumulation and Ser20 phosphorylation. MEFs made from the CHK2 null mice by
Hirao and colleagues (Hirao et al., 2002) have an intact IR-induced G1 checkpoint and
p21 accumulates normally (Jack et al., 2002). Studies in mice have also shown that
mutation of the murine equivalent of human Ser20, (Ser23), did not alter p53
stabilization in response to DNA damage (Wu et al., 2002). Second, siRNA-mediated
knockdown of CHK2 in various p53-proficient cancer cell lines failed to alter IR-induced
p53 stabilization or activation of p53 transcriptional targets (Ahn et al., 2003). Ahn et. al.
(2003) went on to show that there was no difference in CHK2-mediated p53
phosphorylation when CHK2 when isolated from cells with or without damage.
Moreover, Similarly, CHK2 null HCT116 did not alter p53 phosphorylation at Ser-20
when compared to the isogenic parental HCT116 cells (Jallepalli et al., 2003). To
summarize, CHK2 is able to phosphorylate p53 and induce its stabilization. However,
cells have evolved alternate ways to regulate p53, rendering CHK2 dispensable under
certain conditions.

1.6 CHK2 Mutations in Cancers
CHK2 inactivating mutations have been found in various human cancers. Figure 3
outlines a few mutations and their locations have been CHK2 germline mutations have
been linked to increased risk towards familial breast, colon and prostate cancer.
Somatic mutations in CHK2 have also been identified in breast, colon, lung, prostate

23

and lung cancers. Although in mice, loss of CHK2 is not sufficient to induce
transformation, its loss can predispose cells to malignant transformation.
One of the first studies linking CHK2 mutations to cancer was made in a subset
of patients with Li-Fraumeni syndrome, a familial cancer predisposition syndrome, which
is usually characterized by germline mutation of TP53 gene (Bell et al., 1999). LFS is
characterized by early onset of tumor development in multiple organs with a
predominance of breast cancer, brain tumors, adrenal cortical tumors, as well as
leukemias and sarcomas (Li and Fraumeni, 1969; Malkin et al., 1990; Srivastava et al.,
1990; Varley et al., 1997). Patients with CHK2 mutations had intact TP53 gene
indicating that mutations in CHK2 and TP53 were mutually exclusive. This suggests that
CHK2 and p53 might act in the same signaling pathway. Two distinct CHK2 mutations
were identified in LFS patients. First mutation, CHK2 110delC, encodes a C-terminal
truncated protein without any kinase activity (Bartkova et al., 2004). The second
mutation, I157T, is a point mutation in the FHA domain, which can potentially disrupt
CHK2 dimerization, and thereby, prevent DNA damage induced CHK2 activation (Cai et
al., 2009; Schwarz et al., 2003b). Additionally, the CHK2 I157T mutation also impairs
the ability to CHK2 to recognize its substrate, p53 (Falck et al., 2001a; Falck et al.,
2001b)
In addition to LFS, these mutations have also been linked to several other familial
cancers. Analysis of CHK2 110delC mutation in cancer families indicated that this
mutation increases the risk of breast and prostate cancer (Meijers-Heijboer et al., 2002;
Meijers-Heijboer et al., 2003; Seppala et al., 2003). The I157T mutation increases the
risk of developing ovarian, thyroid, kidney, colorectal, bladder carcinomas and leukemia
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(Cybulski et al., 2004; Kilpivaara et al., 2006; Matyjasik et al., 2007; Rudd et al., 2006;
Szymanska-Pasternak et al., 2006). Subsequent studies have identified three additional
CHK2 mutations. S428F, present in the Ashkenazi-Jewish population increases the risk
of breast cancer (Shaag et al., 2005). IvS2 + 1G>A and 5395del has been reported to
increase the risk of breast and prostate cancer (Cybulski et al., 2007; Dong et al., 2003;
Gorski et al., 2005). Sporadic mutations of CHK2 have been found in a broad spectrum
of tumors, including tumors of the breast, lung, vulva, urinary bladder, colon, and ovary,
as well as lymphomas and osteosarcomas (Bartkova et al., 2004; Hangaishi et al.,
2002; Haruki et al., 2000; Miller et al., 2002; Reddy et al., 2002; Sullivan et al., 2002;
Tavor et al., 2001; Tort et al., 2002).
The CHK2 gene is also regulated in cancers through epigenetic modification and
splice variants. Zhang et. al. (2004) reported hypermethylation of CHK2 locus in nonsmall cell lung cancer cell lines and primary lung cancer specimen (Zhang et al.,
2004b). More than ninety different splice variants of CHK2 were detected in stage III
breast cancer. Most of the splice variants disrupt the kinase domain, and therefore, may
serve as dominant negative mutants (Craig and Hupp, 2004).

1.7 Targeting CHK2 in cancer
Given the role of CHK2 in the DDR pathway, CHK2 can potentially be a lucrative
therapeutic target in various cancers. However, given the role of CHK2 in promoting
p53-mediated apoptosis (Hirao et al., 2002; Hirao et al., 2000; Jack et al., 2002;
Jallepalli et al., 2003; Lovly et al., 2008; Takai et al., 2002), it would be critical to
understand the genetic background of cancers, especially their p53 status, before
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considering CHK2 inhibition. Relevance of p53 is further stressed by a study performed
by the laboratory of Michael Yaffe (Jiang et al., 2009). They reported that the stable
knockdown of CHK2 in transformed MEFs with wild-type p53 decreased DNA damageinduced apoptosis. However, loss of CHK2 in p53 null MEFs resulted in an increase in
apoptosis. In support of this observation, numerous other studies have shown that
inhibition of CHK2 in combination with DNA damaging agents provide therapeutic
advantage by disrupting the DNA repair and cell cycle arrest, which results in prolonged
DNA damage and eventually apoptosis. For example, antisense knockdown of CHK2 in
HEK293 cells increased apoptosis by disrupting S- and G2- checkpoints in response to
IR or VP16 treatment (Yu et al., 2001b). Similarly, inhibition of CHK2 using antisense
oligonucleotides (AsODN) increased IR-induced apoptosis in HeLa cells (Gao et al.,
2009). Moreover, CHK2 has been shown to promote release of survivin, an antiapoptotic factor, and promote survival in xenograft models (Lopergolo et al.). CHK2
inhibition also enhanced the level of mitotic catastrophe when used in combination with
either doxorubicin (Castedo et al., 2004) or cisplatin (Vakifahmetoglu et al., 2008).
Various CHK2 specific inhibitors have been developed and tested preclinically
One of theses inhibitors, PV1019, is able to prevent IR-induced apoptosis in mouse
thymocytes (Jobson et al., 2009). This supports the resistance of thymocytes to IRinduced apoptosis in CHK2 null mice (Hirao et al., 2002; Takai et al., 2002).
Interestingly, PV1019 was able to increase apoptosis in ovarian cells lines that had also
been treated with chemotherapeutic agents. Similarly, another potent CHK2 inhibitor,
NSC109555, synergistically increased gemcitabine-induced apoptosis in various
pancreatic cell lines (Duong et al.). In contrast, the CHK2 inhibitor, CCT241533, failed to
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potentiate apoptosis in response to chemotherapy, but increased cell death when cells
were treated with PARP-inhibitors (Anderson et al.).
Since most of the tumors have inactivated p53 either through inactivating
mutations within p53 or through over-expression of MDM2 or MDMX, inhibition of CHK2
could potentially provide a therapeutic advantage if used in combination with
chemotherapeutic agents. Furthermore, CHK2 inhibitors could increase the therapeutic
index of chemotherapy by preventing the detrimental side effect in on other organs.
However, further studies are needed to identify subsets of cancer patients who might
benefit from CHK2 inhibitors and to understand the underlying mechanism by which
CHK2 inhibitors sensitize tumor cells to cell death.
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Fig 1.1 Oligomerization-induced CHK2 activation in response to DNA DSBs
In response to DNA DSBs, ATM phosphorylates CHK2 on Thr68. Thr68
phosphorylation induces CHK2 dimerization through its interaction with the FHA domain
of another CHK2 molecule. Dimerization induces a cascade of cis- and transautophosphorylation event that completely activates the CHK2 kinase.
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Fig. 1.2 Downstream effectors of CHK2
Upon activation, CHK2 phosphorylates a wide-variety of downstream effectors that
mediate cell cycle arrest, DNA repair and/or apoptosis
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Fig. 1.3 Schematic representing location of CHK2 mutations characterized in a
variety of cancers.
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2.1 Abstract
Checkpoints function to maintain genome stability and are essential for normal
development and organismal homeostasis. Perturbations in checkpoint control
contribute to pathological conditions such as cancer, developmental disorders and
neurodegenerative diseases. The checkpoint protein CHK2 is a serine/threonine protein
kinase that becomes activated in response to DNA double strand breaks (DSBs) and its
activity is critical for inducing cell cycle arrest or apoptosis in cells with DNA damage.
CHK2 is an important regulator of p53 as CHK2-deficient mice have defects in p53
stabilization, p53-dependent transcriptional activation, and p53-dependent apoptosis.
Here we show that CHK2 deficient HCT116 and MCF7 cells are fully capable of
activating the p53-signaling pathway in response to VP16 treatment yet fail to efficiently
undergo apoptosis. Inhibition of cIAP1 and cIAP2, two members of the Inhibitor of
Apoptosis (IAP) family, restored apoptosis in CHK2 deficient cells. Interestingly, CHK2
interacted with cIAP1 and cIAP2 but not with the third family member, XIAP. In addition,
CHK2 phosphorylated cIAP2, inhibited its E3 ubiquitin ligase activity in vitro and
extended its half-life in cells. Thus, CHK2 functions as a tumor suppressor protein not
only by activating pro-apoptotic regulators (p53) but also by inhibiting anti-apoptotic
regulators (cIAPs).
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2.2 Introduction
The tumor suppressor protein, Checkpoint Kinase 2 (CHK2), is a serine/threonine
protein kinase that functions in the cellular response to DNA double strand breaks (DNA
DSBs). Heterozygous germline mutations in CHK2 are associated with a p53independent variant form of the Li-Fraumeni syndrome (Bell et al., 1999). Additionally,
CHK2 mutations are also found in sporadic cancers (Dong et al., 2003; Schutte et al.,
2003; Sodha et al., 2002) and down regulation of CHK2 protein has been reported in
bladder carcinomas, breast carcinomas, and lymphomas (Bartkova et al., 2004; Sullivan
et al., 2002; Tort et al., 2002). In response to DNA DSBs, CHK2 promotes cell cycle
arrest and/or apoptosis. It has been proposed that CHK2 mediates these effects
through the regulation of p53. CHK2 functions immediately upstream of p53 by
phosphorylating p53 at serine 20 and promoting its stabilization in response to DNA
DSBs (Chehab et al., 2000; Shieh et al., 2000). In turn, p53 transcribes members of the
Bcl-2 family of pro-apoptotic genes like BAX (Miyashita and Reed, 1995; Reed et al.,
1998), PUMA (Yu et al., 2001), and NOXA (Oda et al., 2000) that drive mitochondrial
membrane permeabilization, release of cytochrome c, and subsequent activation of the
caspase cascade to induce apoptosis. BAX consists of a homo-dimerization/heterodimerization (BH3) domain (Kelekar and Thompson, 1998), a characteristic of all Bcl-2
pro-apoptotic family members and a transmembrane domain. When induced by p53 in
response to DNA damage, BAX translocates to the outer-membrane of mitochondria
and forms a pore (Eskes et al., 1998; Jurgensmeier et al., 1998; Schendel et al., 1997).
This results in the release of cytochrome-c (Bossy-Wetzel et al., 1998; Kroemer et al.,
1997) and apoptosis inducing factor (AIF) (Zamzami et al., 1996) from mitochondria. In
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the cytosol, cytochrome-c forms a complex with Apaf1, a homologue of the
Caenorhabditis elegans protein ced-4, and caspase 9, which triggers caspase activation
and cell death (Adams and Cory, 2002; Aligue et al., 1997)
In response to whole body radiation, CHK2 null mice show defects in several features
of p53 regulation and function including p53 phosphorylation at serine 20, p53
stabilization, activation of p53-target genes and p53-dependent apoptosis (Hirao et al.,
2002; Takai et al., 2002). However, several studies have demonstrated that
phosphorylation of p53 on serine 20 is regulated by kinases in addition to CHK2 and
that CHK2 has substrates in addition to p53. For example, siRNA depletion of CHK2 in
three different cancer cell lines failed to alter p53 stabilization or p53 phosphorylation on
serine 20 (Ahn et al., 2003). In addition, homozygous deletion of CHK2 in HCT116 cells
had no effect on the ability of ionizing radiation (IR) to induce p53 stabilization or serine
20-phosphorylation, but did impair the ability of IR to induce apoptosis (Jallepalli et al.,
2003). Lovly et. al also identified a novel auto-phosphorylation site (S379) that is
required for CHK2 signaling to the apoptotic machinery. A mutant of CHK2 encoding
alanine in place of serine at position 379 (S379A) retains kinase activity but U2OS cells
expressing this mutant are impaired in their ability to undergo apoptosis following
exposure to VP16. This was also true for U2OS cells stably expressing a kinase-dead
mutant of CHK2 (Lovly et al., 2008b). Thus, both kinase activity and S379
phosphorylation are required for the pro-apoptotic effector function of CHK2.
Paradoxically, p53 accumulation, p53 modification (phosphorylation of S20 and
acetylation of K382) (Fig. 2.1) and p53 transcriptional activity (p21, PUMA) (Fig. 2.2)
were similar between VP16 treated cells expressing WT CHK2 and those expressing
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the S379A mutant. These results suggest that cancer cells have evolved additional
ways to regulate p53 in the absence of CHK2 and that CHK2 has additional effectors in
the DNA damage-induced apoptotic pathway. CHK2 has been shown to regulate
BRCA1, E2F-1, MDMX, PML and p73 although the role of these substrates in CHK2mediated apoptosis has not been well established (Chen et al., 2005; Lee et al., 2000;
Pereg et al., 2006; Stevens et al., 2003; Urist et al., 2004; Yang et al., 2002).
This study identifies members of the inhibitor of apoptosis (IAP) family as
downstream effectors of CHK2 in the DNA damage apoptotic response pathway. The
IAP family is defined by the presence of an N-terminal conserved 70 amino acid motif
called Baculovirus IAP Repeat (BIR) (Birnbaum et al., 1994). In this section, I will
introduce three IAP family members, cellular IAP1 (cIAP1), cIAP2 and X-linked IAP
(XIAP) with a focus on cIAP1 and cIAP2. cIAPs and XIAP have three functional
domains: three tandem BIR domains that primarily mediate protein-protein interactions,
a ubiquitin binding domain that mediates interactions with other polyubiquitinated
proteins (Blankenship et al., 2009; Gyrd-Hansen et al., 2008), and a C-terminal RING
domain that confers the E3 ligase activity through which IAPs ubiquitinate their
substrates (Mace et al., 2008). Unlike XIAP, cIAPs have an additional domain, Caspase
Recruitment Domain (CARD), following the UBA domain (Lopez et al., 2011). The
CARD domain regulates the RING activity of the cIAPs through autoinhibition (Fig. 2.3).
Deletion of the CARD domain increases the half-life of cIAP1 from greater than 6 h to
about 2 h.
IAPs, especially, cIAP1, cIAP2 and XIAP, function as endogenous negative
regulators of apoptosis. They inhibit apoptosis through direct regulation of caspases,
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and through caspase-independent mechanisms. In this section, I will focus on the
regulation of caspases by cIAPs and XIAP and introduce the caspase-independent
mechanism in Chapter 3. Among all of the IAP family members, XIAP is the most potent
inhibitor of caspases. Caspases are a family of cysteine proteases that execute
apoptosis in response to various forms of stress (Abe et al., 2002; Barnett et al., 2009).
Normally, caspases exist in an inactive or pro-caspase form. Upon specific stimuli,
caspases undergo auto- and trans-activation through proteolytic cleavage and are
converted to their active forms denoted cleaved caspase (CC). Caspases can be
divided into two categories: a) initiator caspases, like caspase-9 and caspase-8, that
sense the apoptotic stimuli, get activated through auto-proteolytic cleavage, and signal
downstream; b) executioner caspases, like caspase-3 and caspase-7, that get activated
upon proteolytic cleavage by the initiator caspases, and in turn, cleave a variety of
proteins, including PARP (PARP cleavage is a classical marker of apoptosis), to initiate
apoptosis. XIAP can directly bind and inhibit the initiator caspase, caspase-9, as well as
the effector caspases, caspase -3 and caspase -7 (Chai et al., 2001; Deveraux et al.,
1998; Deveraux et al., 1997; Huang et al., 2001; Riedl et al., 2001; Silke et al., 2001;
Takahashi et al., 1998). XIAP blocks the homo-dimerization of caspase-9 and prevents
its activation (Shiozaki et al., 2003). XIAP inhibits the effector caspases through a
different mechanism. XIAP binds to the cleaved forms of caspase-3 and -7and inhibits
their activity by excluding substrate binding (Chai et al., 2001; Riedl et al., 2001; Scott et
al., 2005). Although cIAPs were initially shown to bind and inhibit caspase-3, -7 and -9
in vitro (Deveraux et al., 1998; Labbe et al., 2011), it was later shown that cIAPs can
bind but are not able to inhibit the protease activity of caspases in cells (Eckelman and
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Salvesen, 2006). However, cIAP1 has been shown to ubiquitinate effector caspases
and target active caspases for proteosomal degradation (Choi et al., 2009; Damgaard
and Gyrd-Hansen, 2011; Mica et al., 2004). On the other hand, mono-ubiqutination of
caspase-3 and -7 by cIAP2 might provide novel ways of regulating caspase activity by
cIAPs (Huang et al., 2000). In addition to caspases, cIAPs regulate a multitude of
cellular processes like cell survival (Biton and Ashkenazi; Gill et al., 2009), cell migration
(Oberoi et al., 2012), inflammation (Gyrd-Hansen and Meier, 2010b; Labbe et al., 2011),
and immunity (Bertrand et al., 2009; Damgaard and Gyrd-Hansen, 2011; Wong et al.,
2010) through the NFκB family of transcription factors.
cIAPs have been shown to play a crucial role in several human malignancies and
tumor development. XIAP is upregulated in various cancers (Li et al., 2007; Mizutani et
al., 2007; Tamm et al., 2000). The genetic locus of cIAPs, 11q22, is also amplified in
numerous cancers like multiple myeloma, lymphomas, non-small cell lung carcinoma,
renal carcinoma, and hepatocellular carcinomas (Bashyam et al., 2005; Dai et al., 2003;
Gyrd-Hansen and Meier, 2010b; Imoto et al., 2001). Additionally, more than 50% of
MALT lymphomas harbor the t(11,18)(q21;q21) translocation that results in fusion of the
BIR domains of cIAP2 with the carboxy domain of MALT1 which drives tumor
progression and leads to increased chemo-resistance (Akagi et al., 1999; Dierlamm et
al., 1999). Knockdown of XIAP increases the sensitivity of chemotherapy in colorectal
(Connolly et al., 2009), breast (Lima et al., 2004), lung (Cheng et al.; Hu et al., 2003),
and pancreatic (Lopes et al., 2007) cell lines. Similarly, cIAP2 knockdown also
increases the efficacy of chemotherapy in various cancer cell lines (Karasawa et al.,
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2009; Lopes et al., 2007; Miura et al., 2009; Nagata et al.). Thus IAP inhibition may
provide a promising cancer treatment.
IAPs are able to regulate themselves through their RING domain. Both, cIAPs
and XIAP, are able to auto-ubiquitinate and target themselves for degradation by the
proteosome (Mace et al., 2008). Homo-dimerization of the RING domain is essential for
auto-ubiquitination and proteosomal degradation of IAPs (Mace et al., 2008; Nakatani et
al., 2013). Moreover, cIAP1 can ubiquitinate other members of the IAP family through
hetero-dimerization and promote their destruction (Cheung et al., 2008; Conze et al.,
2005). Numerous endogenous regulators of cIAPs have also been identified to date. For
example, HtrA2/Omi is a serine protease that inactivates cIAPs and XIAP by an
irreversible proteolytic cleavage (Jin et al., 2003; Verhagen et al., 2002; Yang et al.,
2003). Mitochondrial protein, SMAC/DIABLO, binds to the BIR3 domain of cIAPs to
promote their dimerization-induced auto-ubiquitination and proteosomal degradation
(Feltham et al., 2011; Shiozaki and Shi, 2004). On the other hand, SMAC/DIABLO is
thought to abrogate XIAP-mediated caspase inhibition (Huang et al., 2003). In turn,
IAPs can also ubiquitinated and degrade SMAC to form a negative feedback loop (Hu
and Yang, 2003; Morizane et al., 2005). Therefore, small molecules mimicking SMAC
binding to IAPs, also known as SMAC mimetics, are being actively developed for cancer
treatment (Dynek and Vucic, 2013; Fulda, 2012; Mannhold et al., 2010). In numerous
cell lines, SMAC mimetics augment chemotherapy-induced apoptosis in both NFkB –
dependent and –independent manners (Berger et al.; Dai et al., 2008; Huerta et al.; Li et
al.; Stadel et al.; Yang et al., 2011).
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Here we demonstrate that CHK2 deficient cancer cells are impaired in their ability
to undergo apoptosis in response to DNA DSBs, despite normal activation of p53
signaling. Restoration of apoptosis in CHK2 deficient cells was achieved by inhibiting
cIAP1/2 with BV6 or by knocking down cIAP1/2. cIAP1 and cIAP2 co-precipitated with
kinase-active but not kinase-dead CHK2 and CHK2 inhibited the E3 ubiquitin ligase
activity of cIAP2. Thus, CHK2 regulates apoptosis by not only activating pro-apoptotic
regulators (p53) but also by inhibiting anti-apoptotic regulators (cIAP1/2).
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2.3 Material and Methods
Cell Culture and Treatments
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)(Life
Technologies) supplemented with 10% BGS (HyClone) and 1% L-glutamine (SigmaAldrich). HEK293T cells were maintained in DMEM supplemented with 10% FBS
(Atlanta Biologics) and 1% L-glutamine. HCT116 parent, HCT116 CHK2-/- and HCT116
p53-/- cells were obtained from The Core Cell Center at Johns Hopkins University.
HCT116 cells were maintained in McCoys 5A medium (Life Technologies)
supplemented with 10% FBS. MCF7 cells were maintained in DMEM supplemented
with 10% FBS and 1% L-Glutamine. In some cases cells with treated with complete
media containing the indicated concentration of VP16 (Sigma-Aldrich). For treatment of
cells with BV6 (Genentech), cells were incubated with complete media containing 5 mM
BV6 for 4 h. Following that cells were supplemented with complete media containing
DMSO or VP16 to a final concentration of 25 µM. For inhibition of the proteosomal
degradation of proteins, HEK293T cells were treated with complete media containing 50
µM MG132 (Sigma-Aldrich). For measuring the half-life of proteins, cells were grown in
complete media containing 10 µg/mL of cycloheximide (CHX; Sigma-Aldrich).
Constructs, Cloning and Transfections
FLAG-CHK2 WT, FLAG-CHK2 D368N, Myc-CHK2 WT, Myc-CHK2 D368N, His-CHK2
WT, and His-CHK2 D368N have been described (Lovly et al., 2008a). FLAG-cIAP1 was
generated by inserting the Hind III/Eco R1 fragment generated by PCR of cIAP1 cDNA
from PGEX4T-cIAP1 (Roy et al., 1997) into the corresponding sites of 3X-FLAG-CMV10
vector (Sigma-Aldrich). FLAG-cIAP2 was generated by inserting the Hind III/Eco R1
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fragment generated by PCR of cIAP2 cDNA from PGEX4T-cIAP2 (Roy et al., 1997) into
the corresponding sites of 3X FLAG CMV10 vector (Sigma-Aldrich). myc-cIAP2 was
generated by inserting the Bam H1/Eco R1 fragment generated by PCR of cIAP2 cDNA
from pGEX4T-cIAP2 (Roy et al., 1997) into the corresponding sites of pcDNA3.1-myc
vector (Lovly et al., 2008a). FLAG-cIAP2 T35A/C557A mutant were generated using
QuickChange Site-Directed Mutagenesis kits (Stratagene). pcDNA3-myc-XIAP was
purchased from Addgene (Addgene# 11833). CHK2 shRNA
(GAACAGATAAATACCGAACAT and GACTCCAGTGGTAATCTACT) was obtained
from Washington University Genome Center and Children’s Discovery Institute.
HEK293 cells were transfected using Superfect (Qiagen). HEK293 cells were plated at
a density of 0.6X106 cells/6 cm dish. The next day, 3 µg of total plasmid and 20 µl of
Superfect reagent was mixed in a tube containing 200 µl of Opti-MEM media (Life
Technologies) and incubated at room temperature for 5 min. The cocktail was added to
the plates containing 1 ml of complete media. After 6 h, cells were washed with PBS
and grown in complete media. Cells were harvested 24 h post transfection. HEK293T
and HCT116 cells were transfected using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. Briefly, HEK293T or HCT116 cells were plated at a density
of 0.6 x 106 cells/6 cm and 1.5 x 106 cells/6 cm dish respectively. The next day, 2 - 2.5
µg of total plasmid was mixed with 500 µl of Opti-MEM media in tube 1 and incubated at
room temperature for 5 min. In tube 2, 6 - 7.5 µL of Lipofectamine 2000 was mixed with
500 µL of Opti-MEM media and incubated at room temp for 5 min. After 5 min, tube 1
and tube 2 were mixed and incubated at room temperature for 20 – 30 min. After the
incubation, the transfection cocktail was added to the plates containing 2 mL of
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complete media. 24 h post-transfection, the cells were washed with 1X PBS and media
was replaced. For RNAi transfections, Luciferase GL3 duplex and SMARTpool siRNAs
specific to NEMO, cIAP1, cIAP2 and XIAP (ThermoScientific) were transfected using
DharmaFECT siRNA transfection reagent 2 (ThermoScientific). Briefly, HCT116 cells
were plated at a density of 0.3 x 106 cells/60mm dish for the next day transfection. For
transfection, 7.5 µl of 20 µM siRNA was mixed with 300 µl of Opti-MEM media in tube 1,
and 6 µl of Dharmafect 2 was mixed with 300 µl of Opti-MEM media in tube 2. Both the
tubes were incubated at the room temperature for 5 min. Tube 1 was mixed with tube 2
and incubated for an additional 30 min. Meanwhile, the media on the cells was replaced
by 2.5 mL of complete media. Post-incubation, the transfection cocktail was added to
the cells in a dropwise manner. 18 h post-transfection, the media was replaced by 4
mLs of complete media.
Stable cell lines were generated by using lentivirus infection as described previously
(Stewart et al., 2003). Briefly, HEK293T cells were plated at 6 x 105 cells/6 cm dish the
day before transfection. The next day, cells were transfected with a mixture of 1 µg viral
DNA encoding the gene of interest and 1 µg pHR’8.2deltaR packaging plasmid at a ratio
of 8:1 with pCMV-VSV-G envelope plasmid using Mirus LTR1 transfection reagent
(Mirus). Target cells were plated at 1 x 106 cells/10 cm dish the day before infection
with the lentivirus. After HEK293T cells were transfected with viral DNA for 48 h,
supernant from the HEK293T cells containing the viral particles were transferred to the
target cells with the addition of 10 µg/ml protamine sulfate for 4 h. Media containing
virus was then removed and media was replaced. Infected cells were allowed to
recover for 24 h and then were re-infected with the lentivirus. Infected cells were
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trypsinized and plated in media containing puromycin 48 h after the first infection with
lentivirus.
Western blotting, Antibodies and Immunoprecipitation
Cells were lysed in mammalian cell lysis buffer (MCLB (50 mM TrisHCl pH 8.0, 2 mM
DTT, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl,)) supplemented with 1 mM microcystin
(Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), 2 mM PMSF (SigmaAldrich), protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail
(Calbiochem). Clarified lysates were resolved directly by SDS-PAGE and transferred to
nitrocellulose membranes for Western blotting. Membranes were blocked in TBST (20
mM Tris HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) containing 5% nonfat milk for 1h
and incubated overnight in primary antibody diluted in TBST/5% nonfat milk.
Membranes were washed in TBST, incubated with HRP-conjugated secondary antibody
for 1 h in TBST/5% nonfat milk, and washed again in TBST. Membranes were
incubated with ECL (Pierce) and analyzed using a GelDoc Imaging System (BioRad).
Cleaved caspase -3, XIAP, and cIAP2 antibodies were from Cell Signaling. p53, p21,
pS15 p53, pS20 p53, and ubiquitin antibodies were from Santa Cruz Biotechnology.
CHK2, K-48 ubiquitin, and K-63 ubiquitin antibodies were from EMD Milipore. Actin and
Tubulin were from Sigma-Aldrich. cIAP1 antibody was from R & D system. Endogeous
cIAP2 in HCT116 and MCF7 cells was detected using cIAP2 antibody from BD
Biosciences and R&D system respectively. β-catenin antibody was from BD
Biosciences, and GAPDH antibody was from Advanced ImmunoChemical. The antibody
specific for cIAP2 phosphorylated on threonine 35 was generated by immunizing rabbits
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with the phosphopeptide CELYRMS-pT-YSTFP coupled to keyhole limpet hemocyanin
(KLH).
For co-immunoprecipitation, cells were lysed in MCLB. Cell lysates were pre-cleared
with protein A-agarose (Thermo Scientific) and incubated with anti-Flag M2 (SigmaAldrich) or anti-myc 9E-10 (SantaCruz Biotechnology) affinity gel. Immunocomplexes
were washed 4 times with MCLB, eluted by boiling in the Laemmli buffer at 95°C for 5
min, resolved by SDS-PAGE and analyzed by Western blotting.
Cell Death and Caspase-3 Activity Assays
Cell death as measured by Sub-G1 DNA content was assessed using propidium iodide
staining and fluorescent associated cell sorting (FACS) as described previously (Lovly
et al., 2008a). Cell death as measured by annexin and PI double positive cells was
measured using Annexin V : FITC Apoptosis Detection Kit I (BD Biosciences) as per
manufacturers protocol. Caspase-3 activity was measured by utilizing the caspase-3
fluorogenic substrate Ac-DEVD-AFC (SantaCruz Biotechnology). The cells were lysed
in mammalian cell lysis buffer (MCLB: 50 mM Tris HCl pH 8.0, 100 mM NaCl, 2 mM
DTT, 5 mM EDTA, 0.5% NP-40) and incubated with 5 µg of the peptide at 37°C. The
fluorescence was measured over time for a period of 150 min using FLUOstar Optima
(BMG Labtech) and the data was analyzed using FLUOstar version 1.30R3 (BMG
Labtech).
Ubiquitination assay
His tagged CHK2 was purified from bacteria as described previously (Schwarz et al.,
2003a). 300 ng of His-tagged cIAP2 (R&D System) was incubated in the presence or
absence of increasing concentrations (30 ng – 300 ng) or 300ng of His-tagged CHK2
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KA or CHK2 D368N in the ubiquitination buffer (50mM Tris-HCl pH 7.4, 2 mM ATP, 2.5
mM MgCL2, 0.5 mM DTT and 0.05% NP-40) at 30°C for 30 min. 100 ng of recombinant
E1 (Sigma-Aldrich), 300 ng of recombinant UbcH5c (Sigma-Aldrich) and 1 mg of bovine
with either wild type, K68R, or K63R ubiquitin (Sigma-Aldrich) were added to the
reaction. Reactions were incubated for another 60 min at 30°C. Reactions were stopped
by boiling at 95°C for 5 min in the presence of Laemmli buffer.
For inhibiting CHK2 kinase activity, 2 mM of CHK2 inhibitor II hydrate (Sigma-Aldrich) or
AZD-7762 (Axon Medcam BV) were incubated with 300 ng of recombinant his tagged
CHK2 in the ubiquitination buffer for 10 min. Ubiquitination of cIAP2 was then performed
as described above.
Kinase Assays
GFP-Tagged CHK2 was transfected in 293T and immunoprecipitated as described
above. Immunoprecipitated CHK2 was incubated with 5 µg of recombinant recombinant
cIAP2 (R&D system) in complete kinase buffer (50 mM Tris-HCl pH 7.5, 12.5 mM
MgCl2, 1 mM DTT, 440 µM ATP and 7 µCi γ[32P]ATP [>4000 Ci/mmol]) at 37°C for 30
minutes. Samples were boiled, resolved by SDS-PAGE, and transferred onto
nitrocellulose.
High-Resolution nano-LC-Mass Spectrometry.
5 µg of recombinant CHK2 and cIAP2 were incubated in presence or absence of in
ubiquitination buffer (50 mM Tris-HCl pH 7.4, 2 mM ATP, 2.5 mM MgCL2, 0.5 mM DTT
and 0.05% NP-40) at 30°C for 30 min. After the reaction, proteins were first precipitated
using a 2D Clean-up Kit (GE Healthcare Life Sciences) according to the manufacturer’s
protocol. The precipitated proteins were solubilized in 20 ml of 8 M urea, 100 mM Tris,
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pH 8.5. Proteins were reduced with 5mM Tris (2-carboxyethyl)phosphine reducing agent
(Tcep, Thermo Scientific), alkylated with 20 mM Iodoacetamide (IAM; Sigma Aldrich).
The reaction was quenched with 10 mM DTT (Thermo Scientific), followed by digestion
with 1mg LysC (Roche) for 4 h at 37 °C with agitation. The solution was diluted to 2 M
urea and digested overnight with 4 mg trypsin (Sigma-Aldrich) at 37°C on thermomixer.
Digested protein was acidified to 5% formic acid (Fluka) and peptides were desalted
using C4 tip (Glygen) followed by C1 tip (Glygen) according to the manufacturers
protocol.
The endoprotease digests were analyzed by using nano-LC-MS with a linear ion
trap orbitrap mass spectrometer (Orbitrap ELITE) (Thermo Fisher Scientific) (Michalski
et al., 2012). Chromatographic separations were performed by using a nano-LC 2D Plus
(Eksigent, Dublin, CA) for gradient delivery and a cHiPLC-Nanoflex system (15-cm ×
200-µm C18 packing (ChromXP C18-CL, 3 µm, 120 Å; Eksigent). The liquid
chromatograph was interfaced to the mass spectrometer with a nanospray source
(PicoView PV550; New Objective, Woburn, MA). Mobile-phase components were 1%
FA in water (solvent A) and 1% FA in 99% ACN (solvent B). After equilibration of the
column in 98% solvent A/2% solvent B, the samples were injected (10 µl) by using an
AS2 autosampler (Eksigent), at a flow rate of 750 nl/min. The peptides were separated
by using an AcN gradient at 400 nl/min, as follows: isocratic elution at 2% solvent B, 0
to 5 min; 2% solvent B to 25% solvent B, 5 to 110 min; 25% solvent B to 80% solvent B,
to 170 min; 80% solvent B to 2% solvent B, 170 to 175 min; isocratic elution at 2%
solvent B, 175 to 190 min. The total cycle time, including column equilibration, sample
loading, and gradient elution of peptides, was 217 min.
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The survey scans (m/z 350–1200) (MS1) were acquired at 60,000 resolution at
m/z 400) in the Orbitrap in profile mode, and the product-ion mass spectrometry spectra
(MS2) were acquired at 7500 resolution in profile mode, after high energy collisioninduced dissociation. The maximal injection times for the LTQ and Orbitrap were 50 ms
and 200 ms, respectively. The automatic gain-control targets for the LTQ and the
Orbitrap were and 3 × 104 and 1 × 106 respectively. The MS1 scans were followed by
ten MS2 events in the linear ion trap with collision activation in the ion trap (parent
threshold, 15,000; isolation width, 2 Th; normalized collision energy, 30%; activation Q,
0.250; activation time, 30 ms). Dynamic exclusion was activated for 60 s after MS2
acquisition. A repeat count of 3, a repeat duration of 45 s, and a maximal exclusion list
size of 500 were used. The following ion source parameters were used: capillary
temperature, 275°C; source voltage, 2.7 kV; source current, 100 µA; tube lens, 79 V.
The data were acquired by using Xcalibur 2.0.7 (Thermo Fisher).
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2.4 Results
2.4.1 Regulation of p53 by DNA damage is intact in HCT116 cells lacking CHK2
CHK2 promotes apoptosis in a p53-dependent manner in normal cells that have been
exposed to agents that induce DNA double strand breaks (DSBs) (Takai et al., 2002).
We tested whether CHK2 was required for VP16-induced apoptosis in a p53 proficient
colon cancer cell line, HCT116 (Bunz et al., 1998). Parental and CHK2-/- HCT116 cells
were cultured for 48 h in the presence of increasing concentrations of VP16. CHK2-/HCT116 cells underwent significantly less apoptosis (Fig. 2.4A), exhibited reduced
cleaved caspase 3 activity (Fig. 2.4B) and had lower levels of cleaved caspase 3 (Fig.
2.4C) than did parental HCT116 cells. The observed differences between CHK2
proficient and CHK2 deficient cells were lost at higher doses of VP16 (200 mM). Stable
knockdown of CHK2 in HCT116 cells (Fig. 2.5A) and in MCF7 cells, another p53
proficient cancer cell line (Fig. 2.6A), impaired the ability of VP16 to induce cleaved
caspase 3 activity (Fig. 2.5B, 2.6B) and apoptosis (Fig. 2.5C). MCF7 cells are resistant
to DNA damage-induced apoptosis and so higher concentrations of VP16 were used for
these experiments.
p53 was monitored to determine if the reduced apoptotic response of CHK2-/- HCT116
cells to VP16 was due to an inability of these cells to fully activate p53 in response to
DNA DSBs. p53 stabilization (Fig. 2.4C) and phosphorylation on both Ser 15 and Ser 20
(Fig. 2.7A, B) were normal in CHK2-/- HCT116 cells following VP16 treatment. Next, p53
transcriptional activity was assessed by monitoring its downstream effectors. p21 and
BAX accumulated in both parental and CHK2-/- HCT116 cells following VP16 treatment
(Fig. 2.8A) and RNA levels for p21, BAX and PUMA were induced to similar levels in
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both cell lines (Fig. 2.8B). Similarly, p53 stabilization and accumulation of p21 and BAX
were normal in HCT116 and MCF7 cells knocked down for CHK2 (Fig. 2.5A, 2.6A).
Thus, despite normal activation of p53, cells lacking CHK2 were impaired in their ability
to undergo apoptosis in response to DNA DSBs.
CHK2 was depleted in p53-/- HCT116 cells to determine if CHK2 regulated p53independent apoptotic pathways (Fig. 2.9A). Neither p21 or BAX accumulated when
p53 null HCT116 cells were treated with VP16 (Fig. 2.9A). CHK2 depletion did not
significantly affect levels of cleaved caspase 3 in VP16-treated p53 null HCT116 cells
(Fig. 2.9B) but did result in an increase in apoptosis in p53 null cells (Fig. 2.9C). This is
agreement with a previous study reporting that loss of CHK2 in p53 null mouse
embryonic fibroblasts increased apoptosis in response to DNA damage (Jiang et al.,
2009). Taken together, these results suggested that CHK2 has effectors in addition to
p53 that contribute to the p53-dependent apoptotic response of HCT116 cells following
VP16 treatment.

cIAPs provide anti-apoptotic activity in VP16-treated CHK2 null cells
Given that the ability of DNA damage to activate p53 appeared normal in the absence of
CHK2, we next sought to determine why apoptosis was impaired in VP16-treated CHK2/-

cells. The intrinsic apoptotic pathway is regulated downstream of PUMA and BAX by

the mitochondrial protein SMAC/DIABLO (second mitochondrial activator of
caspases/direct IAP binding protein with low pI). In response to apoptotic stimuli, SMAC
is released from the mitochondria into the cytosol where it can bind to members of the
inhibitor of apoptosis (IAPs) and reduce their ability to interact with caspases thereby
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perpetuating the apoptotic signal (Wang, 2001). To determine if cIAPs were protecting
CHK2 null cells from VP16-induced apoptosis, parental and CHK2 null HCT116 cells
were cultured in the presence of BV6, a cIAP1/2 inhibitor, prior to VP16 treatment.
Consistent with our earlier observations, CHK2 deficiency impaired the ability of VP16
to induce cleaved caspase 3 activity (Fig. 2.10A) and apoptosis in HCT116 cells (Fig.
2.10B, C). Importantly, BV6 rescued the ability of VP16 to generate cleaved caspase 3
activity (Fig. 2.10A) as well as apoptosis (Fig. 2.10B, C) in CHK2-/- HCT116 cells. BV6
was also capable of rescuing cleaved caspase activity in VP16-treated CHK2 deficient
MCF7 cells (Fig. 2.11A). cIAP1 loss was used to verify BV6 activity in HCT116 (Fig.
2.10D) and MCF7 (Fig. 2.11B) cells. These results suggested that cIAPs provide antiapoptotic activity in VP16-treated CHK2 null cells and that CHK2 normally functions to
negatively regulate cIAPs in order to drive p53 proficient cells with DNA DSBs into
apoptosis.

cIAP1 and cIAP2 both contribute to reduced apoptosis in CHK2 null cells
Next knockdown experiments were performed to determine if loss of cIAP1 and cIAP2
were both required to rescue cleaved caspase 3 activity in VP16-treated CHK2 null
cells. Given that BV6, which inhibits both cIAP1 and cIAP2, rescued cleaved caspase 3
activity in VP16 treated CHK2 null HCT116 cells and in CHK2 deficient MCF7 cells (Fig.
2.10, 2.11), we depleted both cIAP1 and cIAP2 in parental and CHK2 null HCT116 cells
prior to VP16 treatment (Fig. 2.12A). As seen in Fig. 2.12B and 2.12C, concomitant
depletion of both cIAP1 and cIAP2 was able to rescue VP16 induced apoptosis in CHK2
null HCT116 cells. However individual knockdown of either cIAP2 (Fig. 2.13A) or cIAP1
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(Fig. 2.14B) did not restore levels of apoptosis in VP16-treated CHK2 null cells to those
measured in VP16-treated parental cells (Fig. 2.13B, 2.14B). In fact, depletion of cIAP2
actually impaired the ability of VP16 to induce apoptosis (as measured by levels of
cleaved caspase 3 activity) in both parental and CHK2 null HCT116 cells (Fig. 2.13B).
This was confirmed through the use of individual cIAP2 siRNA (C1-4) from the pooled
siRNA (Fig. 2.13C, D). Finally, depletion of XIAP did not impact cleaved caspase 3
levels (Fig. 2.15A), cleaved caspase 3 activity (Fig. 2.15B) or apoptosis (Fig. 2.15C) in
VP16 treated parental and CHK2 null cells.
Taken together our results suggest that CHK2 promotes apoptosis in response to
DNA damage in at least two ways. CHK2 phosphorylates p53 resulting in the activation
of pro-apoptotic signaling and CHK2 negatively regulates cIAP1 and cIAP2 to turn-off
anti-apoptotic signaling.

CHK2 interacts with and inhibits E3 ligase activity of cIAP2.
To determine how CHK2 might be regulating the IAPs, CHK2 was monitored for its
ability to interact with IAP family members. CHK2 oligomerizes and becomes
hyperphosphorylated through auto/trans-phosphorylation mechanisms when it is
overexpressed in either HEK293 cells or in bacteria (King et al., 2007; King et al., 2006;
Schwarz et al., 2003b). This results in its full activation of CHK2 in the absence of any
DNA damage. By contrast, CHK2 mutants lacking kinase activity fail to become
hyperphosphorylated under these conditions. Thus, HEK293 cells enabled us to monitor
interactions between both kinase-active and kinase-inactive forms CHK2 with IAP family
members. As seen in Fig. 2.16, kinase-active CHK2 co-precipitated with cIAP2 (Fig.
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2.16A lane 2) and cIAP1 (Fig. 2.16B lane 2) but not with XIAP (Fig. 2.16C lane 3).
Interestingly, the ability of CHK2 to interact with cIAP1 and cIAP2 required its kinase
activity as neither cIAP2 (Fig. 2.16A, lane 3) nor cIAP1 (Fig. 2.16B lane 3) coprecipitated with the kinase-inactive CHK2 mutant (CHK2-KD).
Next, experiments were conducted to identify domains in cIAP2 that were required for
its interactions with CHK2. Different cIAP2 deletion mutants (Fig. 2.17A) were
ectopically expressed in HEK293T cells in the presence or absence of either wild-type
or kinase-dead CHK2. As seen in Fig. 2.17B, deletion of the linker region between the
BIR3 domain and the UBA domain abrogated the interaction between CHK2 and cIAP2
(compare lane 14 and lanes 2, 5, 8, and 11). Similar results were obtained with various
cIAP2 deletion mutant created by deleting its functional domains from the C-terminus
(data not shown). This shows that the linker region (L) of cIAP2 mediates its interaction
with CHK2.
When cIAP2 is overproduced in cells, it undergoes homodimerization, autoubiquitination and in this way regulates its own proteasome-mediated degradation
(Bertrand et al., 2008). Thus, we were able to monitor the ability of CHK2 to regulate
cIAP2 turnover when they were co-produced in HEK293T cells. Interestingly, cIAP2
accumulated in cells when it was co-produced with kinase-active (Fig. 2.18, lane 3) but
not with kinase-dead (lane 5) CHK2. Kinase-active CHK2 had modest effects on cIAP1
levels (lane 9) and no apparent effect on XIAP levels (lane 15). Ectopically produced
cIAP1, cIAP2 and XIAP accumulated in cells cultured in the presence of the proteasome
inhibitor MG132 indicating that all three family members were undergoing ubiquitinmediated proteolysis (Fig. 2.18B, lanes 2, 8, and 14). Interestingly, addition of MG132 to
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the culture media failed to increase levels of cIAP2 above the already high levels
observed when cIAP2 and kinase-active CHK2 were co-produced (compare lanes 3 and
4). This indicated that CHK2 inhibited the ability of cIAP2 to promote its own turnover.
To confirm whether CHK2 was indeed regulating the E3 ligase activity of cIAP2, cIAP2
deletion mutants that lacked the RING domain (Fig. 2.18B) were co-expressed with
CHK2. As seen previously, ectopically expressed cIAP2 was rapidly degraded (Fig.
2.18C lane 1 and 5) as cIAP2 levels increased in the presence of MG132 (Fig. 2.13C
compare lanes 1 and 2). However, cIAP2 deletion mutants lacking the RING domain
were already present at high levels and did not accumulate in the presence of MG132
indicating that wild type cIAP2 utilizes its own RING domain to mediate its destruction
(Fig. 2.18C compare lanes 7 and 8; lanes 11 and 12). Wild type, but not kinase-dead,
CHK2 was able to stabilize wild type cIAP2 (Fig. 2.18C lane 3) but failed to stabilize
already high levels of cIAP2 ΔR or cIAP2 ΔC mutants. This provided further evidence
that cIAP2 regulates its own turnover through its E3 ubiquitin ligase activity and that
CHK2 potentially impairs the ability of cIAP2 to degrade itself in the cells. On the other
hand, MG132-treatment resulted in higher levels of cIAP1 (Fig 18A compare lanes 9
and 10) and XIAP (Fig 18A compare lanes 15 and 16) in cells where kinase-active
CHK2 was also produced indicating that cIAP1 and XIAP continued to undergo
ubiquitin-mediated proteolysis even in the presence of CHK2. Consistent with the
conclusion that CHK2 stabilizes cIAP2 by inhibiting its ubiquitin-mediated proteolysis in
vivo , was the observation that the half-life of c-IAP2 was extended from less than 15
min in the absence of CHK2 to approximately 60 min in the presence of CHK2 (Fig 19
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A, B). By contrast, CHK2 did not effect the half-life of cIAP1 (Fig. 2.19 C, D) or XIAP
(Fig. 2.19E, F).
Ubiquitination reactions were performed in vitro with purified proteins to determine if
CHK2 directly inhibited the E3 ubiquitin ligase activity of cIAP2. As seen in Fig. 2.20A,
purified cIAP2 migrated as expected for a 70 kDa protein on SDS-gels (lane 1). cIAP2
became stochiometrically ubiquitinated and ran as a heterogenous population of
polyubiqutinated species when incubated in vitro in the presence of E1, E2 and ubiquitin
(Fig. 2.0A lane 2). The ability of cIAP2 to autoubiquitinate was inhibited when assays
were carried out in the presence of kinase-active (lanes 3-7) but not kinase-dead (lanes
8-12) CHK2. This was evident by the presence of the 70 kDa form of cIAP2 (lanes 3-7)
in blots probed with cIAP2 antibody; the disappearance of the most polyubiquitinated
forms of cIAP2 detected in blots probed with ubiquitin-specific antibodies (Ub blot), as
well as well as those probed with antibodies specific for either K63 or K48 linkage
specific polyubiquitin. The ability of CHK2 to inhibit the E3 ubiquitin ligase activity of
cIAP2 was further tested by including a CHK2 inhibitor in the reaction. As seen in Fig.
2.20B, CHK2 lost the ability to inhibit the autoubiquination of cIAP2 when its kinase
activity was blocked by two different CHK2 inhibitors, CHK2 inhibitor II (Arienti et al.,
2005) and AZD7762 (Zabludoff et al., 2008). Taken together, these results demonstrate
that CHK2 binds to cIAP2 (Fig. 2.16A) and inhibits its E3-ubiquitin ligase activity in a
kinase-dependent manner (Fig. 2.0).
As seen in Fig. 2.20, cIAP2 modification by K63-linked ub was much stronger
compared to the modification by K48-linked ubiquitin. K48 and K63-linked ubiquitin
provide distinct signaling characteristics to a protein. Proteins modified through K48-
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linked ubiquitin are primarily targeted for destruction through the ubiquitin-proteosome
system (Thrower et al., 2000). On the other hand, K63-linked ubiquitin serves as a
signaling scaffold without altering the protein stability (Jacobson et al., 2009; Xu et al.,
2009). K63-linked ubiquitination by cIAPs have been shown to be critical in their
downstream effectors, especially in the NFκB pathway (Bertrand et al., 2011; Bertrand
et al., 2008). Thus, we next questioned if CHK2 could preferentially inhibit the ability of
cIAP2 to promote K63-linked ubiquitination. To test this, we performed the in vitro
ubiquitination assays in the presence of ubiquitin that cannot be linked to the substrates
either through lysine 48 (K48R ubiquitin) or lysine 63 (K63R ubiquitin) (Fig. 2.21). In
agreement with our previous finding, cIAP2 was modified by K63-linked ubiquitin
preferentially over K48-linked ubiquitin modification. In the presence of K63R ubiquitin
(Fig. 2.1 lanes 5 – 8), cIAP2 was not modified by K63-linked ubiquitin. cIAP2
modification by K48-linked ubiquitin was increased and significantly higher compared to
cIAP2 modification seen in the presence of wild-type ubiquitin (compare lanes 2 and 6).
Kinase-active CHK2 was able to inhibit this increased cIAP2 modification through K48linked ubiquitin (compare lanes 10 and 11). Similarly, in the presence of K48R ubiquitin,
cIAP2 failed to be modified by K48-linked ubiquitin and the K63-linked ubiquitin
modification of cIAP2 was unaltered when compared to its modification in the presence
of the wild-type ubiquitin (compare lanes 9 – 12). As seen previously, CHK2 was able to
inhibit cIAP2 modification under these conditions as well.
Taken together these results indicate that in vitro, cIAP2 preferentially modifies its
substrate through K63-linked ubiquitin compared to K48-linked ubiquitin and that CHK2
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is able to inhibit the E3 ubiquitin ligase activity of cIAP2 with no apparent selectivity
towards K63 or K48-linked ubiquitin.

cIAP2 is a CHK2 substrate
We next asked if cIAP2 was a direct substrate of CHK2. As seen in Fig. 2.22A, CHK2
phosphorylated cIAP2 in vitro. To identify sites of phosphorylation, reactions were
scaled up, kinase assays were performed in the presence of unlabeled ATP and
reaction products were subjected to mass spectrometry. This analysis identified
threonine (Thr) 35 as a CHK2 phosphorylation site in vitro. Threonine 35 represented a
consensus CHK2 phosphorylation site and was conserved across species (Fig. 2.22B).
Sequence alignment indicated that the residues surrounding Thr35 were conserved in
cIAP1 but were not conserved in XIAP (Fig. 2.2B). To determine if cIAP2 was
phosphorylated on Thr35 in a CHK2-dependent manner in cells, cIAP2 was coproduced with kinase-active CHK2, kinase-dead CHK2 or CDC25C as a negative
control. A mutant of cIAP2 lacking E3 ubiquitin ligase activity (Huang et al., 2000) was
expressed to eliminate proteasome-mediated degradation of cIAP2. Thr35
phosphorylation was monitored using a phosphospecific Thr35 antibody. As seen in Fig.
2.22C, cIAP2 was phosphorylated on Thr35 when it was co-produced with kinase-active
(lane 2) but not kinase-dead (lane 3) CHK2 in HEK293T cells. The antibody was
specific for Thr35-phosphorylated cIAP2 as a mutant of cIAP2 encoding alanine in place
of Thr35 was not recognized by the phospho-specific antibody (lane 5).
We next determined if Thr35 was essential for CHK2-mediated stabilization of
cIAP2. Consistent with our previous observation, CHK2 promoted accumulation of wild
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type cIAP2 (Fig. 2.3A compare lanes 1 and 3).
The cIAP2 mutant that cannot be phosphorylated on threonine 35 (cIAP2 T35A)
underwent rapid degradation which was inhibited by the proteosome inhibitor MG132.
CHK2 was able to stabilize the cIAP2 T35A mutant just like wild type cIAP2 (compare
lanes 3 and 9). This suggested that phosphorylation of Thr35 was not sufficient to drive
cIAP2 accumulation. cIAP2 contains three additional CHK2 consensus phosphorylation
sites (RXXS/T), including S81, T175, and T261. Substitution of all four sites for alanine
also did not impair the ability of CHK2 to regulate cIAP2 (Fig. 2.23B lanes 3, 7, 11, and
15). In addition to Thr35, mass spectrometry has also identified Ser155 and Ser566
residues on cIAP2 as additional CHK2 phosphorylation sites. I am currently in the
process of mutating these residues to alanine and analyzing the effect of these
mutations of CHK2-mediated cIAP2 stabilization.
Taken together our results suggest that CHK2 promotes apoptosis in response
to DNA damage in at least two ways. CHK2 phosphorylates p53 resulting in the
activation of pro-apoptotic signaling and CHK2 negatively regulates cIAPs to turn-off
anti-apoptotic signaling.
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Discussion
Initial loss of function studies in mice and in cells derived from these mice established
CHK2 as a key regulator of p53 in the DNA damage response pathway (Hirao et al.,
2002; Takai et al., 2002). DNA DSBs activate ATM, which in turn phosphorylates CHK2,
leading to its full activation. Activated Chk2 phosphorylates p53 on Ser 20 – a key
modification to promote p53 stabilization (Chehab et al., 2000; Shieh et al., 2000). Here
we demonstrate that CHK2 is dispensable for p53 phosphorylation on Ser 20 in two
different p53 proficient cancer cell lines (HCT116 and MCF7) following VP16 treatment.
That cancer cells have redundant protein kinases that phosphorylate p53 on serine 20
in response to DNA damage has been observed previously (Ahn et al., 2003; Jallepalli
et al., 2003).
Paradoxically, p53 regulation (phosphorylation of Ser 15 and Ser 20) and function
(induction of p21, BAX and PUMA) appeared normal in CHK2 deficient HCT116 and
MCF7 cells following VP16 treatment, yet these cells were impaired in their ability to
undergo apoptosis. This led us to investigate whether CHK2 regulated proteins
downstream of p53 in the intrinsic apoptotic pathway that had more proximal roles in
regulating the executors of apoptosis. We observed specific interaction between CHK2
and cIAPs, but not with XIAP. Moreover, inhibition of cIAP1 and cIAP2 through the
SMAC mimetic, BV6, rescued levels of apoptosis in CHK2 deficient HCT116 and MCF7
cells to levels measured in CHK2 proficient parental cells. Members of the IAP family
(XIAP, cIAP1 and cIAP2) are potent inhibitors of cell death in response to various stress
signals including DNA DSBs (de Almagro and Vucic, 2012). cIAPs are known to
regulate cell death either through regulation of caspases or through regulation of the
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NF-κB pathway (Gyrd-Hansen and Meier). cIAPs can bind to active form of caspases
and target them for ubiquitin dependent proteosomal degradation (Choi et al., 2009).
Inhibition of both cIAP1 and cIAP2 using siRNA rescued apoptosis in CHK2 null cells to
levels comparable to that of VP16- treated parental cells. Individual loss of cIAP1 or
cIAP2 alone was not sufficient to increase cell death in cells lacking CHK2. Thus, cIAPs
provided anti-apoptotic activity in VP16-treated CHK2 deficient cells. This suggested
that CHK2 normally functions to inhibit cIAPs and in this way sensitizes cells with DNA
DSBs to p53-dependent apoptosis. In support of this, CHK2 inhibited the E3 ubiquitin
ligase activity of cIAP2 in vitro and extended its half-life in cells. Although CHK2 bound
to cIAP1, we were unable to detect alterations in the half-life of cIAP1 in the presence of
CHK2. cIAP1 is known to heterodimerize with cIAP2 and target it for degradation (Silke
et al., 2005). Thus, CHK2 may regulate cIAP1 indirectly through cIAP2.
The ability of CHK2 to bind to and regulate cIAP2 required the kinase activity of CHK2.
This suggested that CHK2 phosphorylated cIAP2 to inhibit its E3 ubiquitin ligase
activity. Indeed, we demonstrated that CHK2 phosphorylates cIAP2 on Thr35 in vitro
and cIAP2 is phosphorylated on Thr35 when co-produced with CHK2 in cells. CHK2
phosphorylates its substrate using the consensus motif: LXRXXpS/T (O'Neill et al.,
2002). Interestingly, cIAP2 contains four CHK2 consensus motifs including Thr35
(LXRXXpT35), Ser81 (RXXS81), Thr145 (RXXT145), and Thr261 (RXXpT261) and all the
sites are evolutionarily conserved. Mass spectrometry of in vitro phosphorylated cIAP2
identified Thr35 but not others as a site of CHK2 phosphorylation site.
cIAP1 and cIAP2 contain four distinct functional domains including three consecutive
BIR domains that mediate protein-protein interactions, a ubiquitin binding (UBA) domain
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that binds to poly-ubiquitinated proteins, a C-terminal RING domain that ubiquitinates its
substrates and a caspase recruiting domain (CARD), which has been proposed to
regulate the activity of the RING domain (Lopez et al., 2011). The structure of the ring
domain of cIAP2 indicates that it exists as a dimer and dimerization of the ring domain is
essential for its function (Mace et al., 2008). Thr35 resides within the first BIR1 domain
of cIAP2 and this domain may have a role in dimerization (Lin et al., 2007; Zhou et al.,
2005). The first BIR domain has been shown to be important for maintaining the E3
ligase activity of the cIAP2-MALT1 fusion protein found in MALT Lymphoma (Zhou et
al., 2005). Furthermore, AKT phosphorylates the BIR domain of XIAP, thereby
disrupting dimerization and inhibiting its E3 ubiquitin ligase activity (Dan et al., 2004;
Mace et al., 2008). cIAP2 is known to homodimerize and to heterodimerize with cIAP1
(Silke et al., 2005). Thus, a logical hypothesis is that phosphorylation of cIAP2 on
Thr35 by CHK2 disrupts cIAP2 homo/hetero-dimerization thereby inhibiting its E3
ubiquitin ligase activity. However, we have found that a mutant of cIAP2 encoding
alanine for threonine at position 35 can still be regulated by kinase-active CHK2
suggesting there may be additional regulatory mechanisms that remain to be identified.
Moreover, mutation of Thr35 alone or in combination with the other CHK2 consensus
sites failed to abrogate the effect of CHK2 on cIAP2 stabilization. Mass spectrometry
has also identified two additional residues, Ser155 and Ser566, on cIAP2 as CHK2
phosphorylation sites. Ser155 is present in the BIR2 domain of cIAP2 which has been
previously shown to be important for caspase binding (Eckelman and Salvesen, 2006).
More importantly, Ser566 is present in the RING domain of cIAP2. Analysis of the RING
domain indicates that this residue might be present in the hydrophobic core, and
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therefore, phosphorylation of Ser566 might disrupt the RING domain and the E3 ligase
activity of cIAP2. Ser566 is conserved in cIAP1 but is mutated to an alanine in XIAP.
Given that we have observed CHK2 interaction with cIAP1 and cIAP2, but not XIAP,
Ser566 has a strong potential for mediating the effects of CHK2 by disrupting cIAP2’s
RING activity.
In summary, we have demonstrated that in p53 proficient cancer cells, CHK2 is
dispensable for p53 activation in response to DNA DSBs. However, apoptosis is
impaired in the face of p53 signaling because the cIAPs inhibit apoptosis downstream of
p53. We conclude that CHK2 normally functions to inhibit cIAPs and in this way
sensitize cells with DNA DSBs to p53-dependent apoptosis (Fig. 2.4). These studies
have implications for how CHK2 inhibitors might be used clinically. On the one hand,
CHK2 inhibitors would be expected to prevent the activation of p53 by IR or
chemotherapy in normal cells, thereby serving as a radio- or chemo-protector. On the
other hand, loss of CHK2 in p53 deficient cancer cells has been shown to enhance
apoptosis in response to DNA damage (Hirao et al., 2002; Jallepalli et al., 2003; Lovly et
al., 2008a; Takai et al., 2002). Thus, one might be able to protect normal cells in the
body from the damaging side effects of treatment while at the same time enhance tumor
cell killing with CHK2 inhibitors.
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Fig. 2.1 CHK2 is not required for post-translational modification of p53 in VP16treated U2OS cells
(A) Cell lysates of parental U2OS (FRT) cells and U2OS cells stably expressing WT and
mutant forms of CHK2 were prepared and subjected to western blotting for the indicated
proteins
(B, C) Parental U2OS (FRT) cells and U2OS cells stably expressing WT and mutant
forms of CHK2 were treated with 10µM VP16 for the indicated periods of time. Cell
lysates were prepared and subjected to western blotting for the indicated proteins
These experiments were performed by Dr. Christine Lovly
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Fig. 2.2 CHK2 activity is dispensable for p53 transcriptional activity in VP16
treated U2OS
(A) Parental U2OS (FRT) cells and U2OS cells stably expressing WT and mutant forms
of CHK2 were treated with 10µM VP16 for the indicated periods of time. Cell lysates
were prepared and subjected to western blotting for the indicated proteins
(B) Parental U2OS (FRT) cells and U2OS cells stably expressing WT and mutant forms
of CHK2 were treated with 10µM VP16 for the indicated periods of time. Total RNA was
isolated and subjected to qPCR for p21 and GAPDH
These experiments were performed by Dr. Christine Lovly
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Fig. 2.3 Schematic of domain structure of the IAP family
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Fig 2.4 CHK2 promotes VP16-induced apoptosis in HCT116 cells
(A, B, C) Parental and CHK2-/- HCT116 cells were treated with VP16 at the indicated
concentrations for 48 h. The percentage of cells containing sub-2N DNA content was
assessed by propidium iodide (PI) staining followed by flow cytometry (A). Cell lysates
were prepared and assayed for cleaved caspase 3 activity as described in Materials
and Methods (B) or were subjected to Western blotting with the indicated antibodies (C).
The results in panels A, and B are presented as mean (± s.e.m.) of three or more
independent experiments. *p<0.05, **p<0.005, ***p<0.0005, n.s. (not significant)
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Fig 2.5 Stable knockdown of CHK2 abrogates VP16-induced apoptosis in HCT116
cells.
(A, B, C) Parental HCT116 cells stably expressing either GFP shRNA (control) or CHK2
shRNA were treated with 25 mM VP16 for 48 h. Cell lysates were subjected to Western
blotting (A), or were assayed for cleaved caspase 3 activity (B). The percentage of cells
containing sub-2N DNA content was assessed by PI staining followed by flow cytometry
(C).
The results in panels A, B, E and F are presented as mean (± s.e.m.) of three or more
independent experiments. ***p<0.0005
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Fig. 2.6 CHK2 promotes VP16-induced apoptosis in MCF7 cells
(A, B) MCF-7 cells stably expressing control (luciferase) or CHK2 shRNA were cultured
in the presence of VP16 at the indicated concentrations for 72 h. Cell lysates were
prepared and were subjected to Western blotting with the indicated antibodies (A) or
assayed for cleaved caspase 3 activity (B).
The results in panels A, B, E and F are presented as mean (± s.e.m.) of three or more
independent experiments. **p<0.005, ***p<0.0005
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Fig. 2.7 CHK2 is dispensable for p53 stabilization and phosphorylation in
response to VP16 treatment
(A) Parental HCT116 cells or HCT116 cells null for either CHK2 (CHK2-/-) or p53 (p53-/-)
were cultured in the presence of 25 µM of VP16 for the indicated times. Cell lysates
were subjected to Western blotting with the indicated antibodies.
(B) Parental HCT116 cells or HCT116 cells null for either CHK2 (CHK2-/-) or p53 (p53-/-)
were cultured in the presence of indicated concentrations of VP16 for 8 h. Cell lysates
were subjected to Western blotting with the indicated antibodies.
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Fig. 2.8 Loss of CHK2 does not affect VP16-induced p53 transcriptional activity
(A) Parental and CHK2-/- HCT116 cells were treated with VP16 at the indicated
concentrations for 48 h. Cell lysates were prepared and subjected to Western blotting
with the indicated antibodies.
(B) Parental and CHK2-/- HCT116 cells were cultured in the presence of 25 µM VP16 for
48 h. Total RNA was isolated and was subjected to qPCR for the indicated genes.
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Fig. 2.9 CHK2 is dispensable for VP16-induced cleaved caspase 3 activity in p53-/HCT116 cells
(A, B, C) p53-/- HCT116 cells stably expressing either GFP shRNA (control) or CHK2
shRNA were treated with 25 µM VP16 for 48 h. Cell lysates were subjected to Western
blotting (A), or were assayed for cleaved caspase 3 activity (B). The percentage of cells
containing sub-2N DNA content was assessed by PI staining followed by flow cytometry
(C).
The results in panels A, B, E and F are presented as mean (± s.e.m.) of three or more
independent experiments. *p<0.05
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Fig. 2.10 Inhibition of cIAP using SMAC mimetic, BV6, rescues VP16-induced
apoptosis in CHK2 null cells
(A, B, C, D) Parental and CHK2-/- HCT116 cells were cultured in the presence of 5 µM
BV6 for 4 h followed by 25 µM VP16 for an additional 48 h. Cell lysates were prepared
and assayed for cleaved caspase-3 activity (A). The percentage of cells containing sub2N DNA content was assessed by PI staining followed by flow cytometry (B).
Percentage of annexin V and PI double positive cells were assessed by flow cytometry
(C). Cell lysates were also subjected to western blotting with the indicated antibodies
(D).
The results in panels A are represented as mean ± s.e.m. and represent three or more
independent experiments. ***p<0.0005, **p<0.005, n.s. (not significant)
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Fig. 2.11 BV6 rescues VP16-induced apoptosis in MCF7 cells lacking CHK2
(A, B) MCF7 cells stably expressing control (luciferase (Luc)) or CHK2 shRNA were
cultured in the presence of 5 µM BV6 for 4 h followed by 200 µM VP16 for an additional
72 h. Cell lysates were prepared and assayed for cleaved caspase-3 activity (A) or
subjected to Western Blotting for the indicated antibodies (B).
The results in panels A are represented as mean ± s.e.m. and represent three or more
independent experiments. ***p<0.0005, n.s. (not significant)
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Fig. 2.12 cIAP1 and cIAP2 are both required for inhibition of VP16-induced
apoptosis in CHK2 null cells
(A, B, C) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
pooled cIAP1 and cIAP2 (C1 + C2) siRNAs for 18 h were cultured in the presence of
vehicle (DMSO, -) or 25 µM VP16 (+) for an additional 48 h. Cell lysates were prepared
and subjected to Western blotting with the indicated antibodies (A) or were assayed for
cleaved caspase-3 activity (B). Percentage of annexin V and PI double positive cells
were assessed by flow cytometry (C).
The results in panels A are represented as mean ± s.e.m. and represent three or more
independent experiments. ***p<0.0005, n.s. (not significant)
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Fig. 2.13 cIAP2 loss reduced VP16-induced apoptosis in HCT116 cells
(A, B) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or pooled
cIAP2 (C2) siRNAs for 18 h were cultured in the presence of vehicle (DMSO, -) or 25
µM VP16 (+) for an additional 48 h. Cell lysates were prepared and subjected to
Western blotting with the indicated antibodies (A) or were assayed for cleaved caspase3 activity (B).
(C, D) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
individual cIAP2 (C2.1 – C2.4) siRNAs for 18 h were cultured in the presence of vehicle
(DMSO, -) or 25 µM VP16 (+) for an additional 48 h. Cell lysates were prepared and
subjected to Western blotting with the indicated antibodies (C), or were assayed for
cleaved caspase-3 activity (D).
The results in panel B, and D, and F are presented as mean (± s.e.m.) of two or more
independent experiments. *p<0.05, **p<0.005, ***p<0.0005.
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Fig. 2.14 Loss of cIAP1 alone does not affect VP16-induced apoptosis in HCT116
cells
(A, B) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
individual cIAP1 (C1.1 – C1.3) siRNAs for 18 h were cultured in the presence of vehicle
(DMSO, -) or 25 µM VP16 (+) for an additional 48 h. Cell lysates were prepared and
subjected to Western blotting with the indicated antibodies (A) or were assayed for
cleaved caspase-3 activity (B).
The results in panel B is presented as mean (± s.e.m.) of three or more independent
experiments. *p<0.05, ***p<0.0005.
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Fig. 2.15 Loss of XIAP does not affect VP16-induced apoptosis in HCT116 cells.
(A, B, C) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
pooled XIAP siRNAs for 18 h were cultured in the presence of vehicle (DMSO, -) or 25
µM VP16 (+) for 48 h. Cell lysates were prepared and subjected to Western blotting with
the indicated antibodies (A) or were assayed for cleaved caspase-3 activity (B).
Percentage of annexin V and PI double positive cells were assessed by flow cytometry
(C)
The results in panel B, and C are presented as mean (± s.e.m.) of three or more
independent experiments. *p<0.05, **p<0.005, ***p<0.0005.
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Fig. 2.16 Wild type CHK2 binds to cIAP1 and cIAP2 but not XIAP
(A, B, C) HEK293T cells were transfected with plasmids encoding tagged forms of the
indicated proteins for 18 h. Cells were then cultured in the presence of 50 µM MG132
for an additional 6 h. Cell lysates were prepared and either resolved directly by SDSPAGE (Total lysate) or were incubated with either anti-Flag (A, C) or anti-Myc affinity gel
(B) and precipitates were resolved by SDS-PAGE. Western blotting was performed with
antibodies specific for the indicated proteins.
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Fig. 2.17 cIAP2 Linker region between BIR3 and UBA domain mediates its
interaction with CHK2
(A) Schematic of domain structure of wild type (1R) and deletion mutants of cIAP2 (2R,
3R, LR, and UR).
(B) HEK293T cells were transfected with plasmids encoding tagged forms of the
indicated proteins for 18 h. Cells were then cultured in the presence of 50 µM MG132
for an additional 6 h. Cell lysates were prepared and either resolved directly by SDSPAGE (Total lysate) or were incubated with anti-Flag and precipitates were resolved by
SDS-PAGE. Western blotting was performed with antibodies specific for the indicated
proteins.
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Fig. 2.18 CHK2 promotes cIAP2 accumulation which requires RING domain
mediated cIAP2 degradation.
(A) HEK293T cells were transfected with plasmids encoding tagged forms of the
indicated proteins for 18 h. Cells were then cultured in the presence of vehicle (-,
DMSO) or 50 µM MG132 (+) for an additional 6 h. Cells lysates were subjected to
Western blotting with the indicated antibodies.
(B) Schematic of domain structure of wild type and deletion mutant cIAP2
(C) HEK293 cells were transfected with plasmids encoding tagged forms of the
indicated proteins for 18 h. Cells were then cultured in the presence of vehicle (-,
DMSO) or 50 µM MG132 (+) for an additional 6 h. Cells lysates were subjected to
Western blotting with the indicated antibodies.
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Fig. 2.19 CHK2 increases the half-life of cIAP2 but fails to alter the half-life of
cIAP1 and XIAP
(A, B) HEK293 cells were transfected with plasmids encoding the indicated proteins for
24 h. Cells were then cultured in the presence of 10 µg/ml cycloheximide (CHX) for the
indicated times. Cell lysates were prepared and either resolved directly by SDS-PAGE
(Total Lysate) or were incubated with anti-Flag affinity gel and precipitates were
resolved SDS-PAGE and analyzed by Western blotting. (A) cIAP2 levels were
quantified using densiometry from 3 independent experiments like the one shown in
panel A (B). Results are represented as mean (± s.e.m.). *p<0.05, **p<0.005
(C, D) HEK293T cells were transfected with plasmids encoding the indicated proteins
for 24 h. Cells were then cultured in the presence of 10 µg/ml cycloheximide (CHX) for
the indicated times. Cell lysates were prepared and subjected to Western blotting for the
indicated antibodies (C). cIAP1 levels were quantified using densiometry from 3
independent experiments like the one shown in panel C (D). Results are represented as
mean (± s.e.m.). ***p<0.005
(E, F) HEK293T cells were transfected with plasmids encoding the indicated proteins
for 24 h. Cells were then cultured in the presence of 10 µg/ml cycloheximide (CHX) for
the indicated times. Cell lysates were prepared and subjected to Western blotting for the
indicated antibodies (E). XIAP levels were quantified using densiometry like the one
shown in panel C (F).
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Fig. 2.20 CHK2 inhibits the E3 ubiquitin ligase activity of cIAP2 in vitro
(A) cIAP2 was incubated in the absence (-) or presence (+) of increasing concentrations
of either CHK2 WT or CHK2 KD for 30 min in ubiquitination buffer at 30°C.
Ubiquitination reactions were then carried out in vitro as described in Materials and
Methods. Reactions were terminated by boiling in Laemmli sample buffer, resolved by
SDS-PAGE and analyzed by Western blotting for the indicated proteins or protein
modifications.
(B) cIAP2 was incubated in the absence (-) or presence (+) of either CHK2 WT or CHK2
KD with or without 2 mM of CHK2 inhibitor II or AZD7762, at 30°C for 30 min in
ubiquitination buffer. Ubiquitination reactions were then carried out in vitro as described
in the Materials and Methods. Reactions were terminated by boiling in Laemmli sample
buffer, resolved by SDS-PAGE and analyzed by Western blotting for the indicated
proteins or protein modifications.
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Fig. 2.21 CHK2 inhibits both K63- and K48-linked ubiquitin modification of cIAP2
in vitro
(A) cIAP2 was incubated in the absence (-) or presence (+) of either CHK2 WT or CHK2
KD at 30°C for 30 min in ubiquitination buffer. Ubiquitination reactions were then carried
out in vitro with the indicated mutants of ubiquitin as described in the Materials and
Methods. Reactions were terminated by boiling in Laemmli sample buffer, resolved by
SDS-PAGE and analyzed by Western blotting for the indicated proteins or protein
modifications.
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Fig. 2.22 CHK2 phosphorylates cIAP2 on Thr35
(A) GFP-tagged CHK2 was precipitated from 293T cells and incubated with
recombinant human cIAP2 in the presence of complete kinase buffer. Reactions were
resolved by SDS-PAGE and visualized by autoradiography.
(B) Sequence alignment of cIAP2 Thr35 and surrounding residues.
(C) HEK293T cells were transfected with plasmids encoding the indicated proteins for
24 h. Cell lysates were prepared and either resolved directly by SDS-PAGE (Total
Lysate) or were incubated with anti-Flag affinity gel and precipitates were resolved
SDS-PAGE and analyzed by Western blotting.
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Fig. 2.23 Potential CHK2 target residues of cIAP2 do not play a role in CHK2mediated cIAP2 stabilization
(A, B) HEK293T cells were transfected with plasmids encoding tagged forms of the
indicated proteins for 18 h. Cells were then cultured in the presence of vehicle (-,
DMSO) or 50 µM MG132 (+) for an additional 6 h. Cells lysates were subjected to
Western blotting with the indicated antibodies.
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Fig. 2.24 CHK2 promotes VP16-induced apoptosis through phosphorylation of
p53 and inhibition of cIAPs
(A) DNA DSBs activate ATM, which in turn phosphorylates CHK2. CHK2
homodimerizes, which leads to additional phosphorylation and activation. Activated
CHK2 phosphorylates p53 on Ser20 leading to p53 accumulation. In cancer cells
lacking CHK2 other kinases phosphorylate p53 on Ser20. p53 induces expression of
the pro-apoptotic proteins BAX and PUMA. This leads to mitochondrial membrane
permeabilization and release of cytochrome-c. Cytochrome-c interacts with Apaf-1 and
activates the caspase cascade to execute apoptotic cell death. cIAPs oppose the
apoptotic program and CHK2 binds to, phosphorylates and inhibits the E3 ubiquitin
ligase activity of cIAP2 thereby sensitizing cells to p53 mediated apoptosis. In CHK2
deficient cancer cells the ability of DNA DSBs to induce p53-dependent apoptosis is
impaired.
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Chapter 3:
Role of CHK2 in the extrinsic apoptotic pathway through the regulation of NFκB
(Unpublished Data)
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3.1 Abstract
Chemotherapeutic agents are widely used in cancer treatment. Most chemotherapeutic
drugs cause DNA damage and induce apoptosis either through mitochondrial
permeabilization (intrinsic apoptosis) or death-receptor activation (extrinsic apoptosis).
The checkpoint kinase CHK2, is activated in response to DNA damage and has
traditionally been proposed to promote cell death through the mitochondrial pathway.
Here, we show that CHK2 can potentially play a key role in death receptor-induced
apoptosis through negative regulation of the NFκB pathway. In response to DNA
damage, CHK2 inhibited early activation of NFκB and prevented upregulation of its prosurvival targets. CHK2 was also required for VP16-mediated sensitization of HCT116
cells to the TNFα superfamily member, TRAIL. Thus, CHK2 serves at the crossroad of
the intrinsic and extrinsic apoptosis pathways and has a much broader role in cell death
than its role in the regulation of the tumor suppressor protein, p53.
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3.2 Introduction
Current cancer therapies, for example, chemotherapy and ionizing radiation (IR), exert
their anti-tumor effect by triggering apoptosis in cancer cells. The checkpoint kinase,
CHK2, plays a key role in DNA damage-induced apoptosis (Hirao et al., 2002; Hirao et
al., 2000; Jallepalli et al., 2003; Lovly et al., 2008). CHK2 null mice are protected from
whole body radiation, and over-expression of CHK2 can promote apoptosis in response
DNA damaging agents like VP16 (Hirao et al., 2000; Lovly et al., 2008; Takai et al.,
2002). Traditionally, it was proposed that CHK2 signals to the apoptotic machinery
through regulation of the tumor suppressor, p53. Recent studies have challenged the
idea that the only role of CHK2 in apoptosis is mediated through p53. I, along with
several other groups have previously shown that cells lacking CHK2 are impaired in
their ability to induce apoptosis despite normal p53 regulation (Ahn et al., 2000; Chen et
al., 2005; Lopergolo et al.; Pereg et al., 2006). Moreover, CHK2 can promote apoptosis
in a p53-independent manner through the regulation of downstream proteins like E2F-1,
PML, Che1 and survivin (Bruno et al., 2006; Lee et al., 2000; Lopergolo et al.; Stevens
et al., 2003; Venere et al., 2002; Yang et al., 2002). However, the role of these proteins
as a CHK2 effector in response to DNA damage has not been well established.
Previously, I demonstrated that CHK2 can bind to and phosphorylate cellular inhibitor of
apoptosis protein, cIAP2, to inhibit its E3 ligase activity. Furthermore, CHK2-mediated
inhibition of cIAPs is essential for DNA damage-induced apoptosis in p53 proficient cell
lines. cIAPs are members of the Inhibitor of Apoptosis (IAP) family that serve as
negative regulators of apoptosis. Although, cIAPs were initially shown to inhibit the
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caspase activity directly, recent studies have indicated that cIAPs are unable to regulate
active caspases under physiological conditions. However, cIAPs can ubiquitinate
cleaved forms of effector caspase and target them for proteosomal degradation. cIAPs
can also inhibit apoptosis by regulating the activation of the NFκB family of transcription
factors. Moreover, the cIAP2 promoter is highly responsive to NFκB activity and helps in
setting a “feed-forward” activation loop that actively promotes cell survival (Chu et al.,
1997; Mahoney et al., 2008a). Here we identified CHK2 as a novel regulator of NFκB
pathway. CHK2 inhibits NFκB activation through inhibition of the E3 ubiquitin ligase
activity of cIAPs.
The NFκB family contains five family members: p50, p52, RelA, RelB and c-Rel.
While all the members of the NFκB family share a Rel homology domain in their Nterminus, a subfamily including RelA, RelB and c-Rel also contain a trans-activation
domain in their C-terminal protein domain. NFκB dimers bind to κB sites within the
promoters/enhancers of target genes and regulate transcription through the recruitment
of co-activators and co-repressors. The NFκB pathway is divided into two distinct
pathways: a) the canonical pathway, and b) the non-canonical pathway. In this chapter I
will focus on the canonical pathway and the role that cIAPs play in this pathway.
The canonical NFκB pathway is activated by various stimuli including DNA
damage, Tumor Necrosis Factor α (TNFα), TNF Related Apoptosis inducing Ligand
(TRAIL), Fas ligand (FasL) and others. All these stimuli eventually converge on the
activation of the inhibitors of κB (IκB) kinase (IKK) complex. The hetero-trimeric IKK
complex consists of two catalytic subunits, IKKα and IKKβ, and a regulator unit, IKKγ,
which is also known as NFκB Essential Modifier (NEMO). Upon activation, IKKα or
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IKKβ, phosphorylate the IκB inhibitor protein, IκBα (DiDonato et al., 1996; Mercurio et
al., 1997; Zandi et al., 1997). Normally, IκBα masks the nuclear localization sequence
(NLS) of NFκB transcription factors and retains them in the cytosol (Beg et al., 1995;
Henkel et al., 1992). Upon phosphorylation by the IKK on Ser32, IκBα is recognized by
the SCPβTrCP E3 ubiquitin ligase and targeted for proteosomal destruction (Brown et al.,
1995; Chen et al., 1995; DiDonato et al., 1996). As a result the NFκB transcription
factors like p50/p65 move into the nucleus where they promote and inhibit transcription
of a wide variety of genes.
Different stimuli activate IKK through distinct mechanisms. One of the most
characterized activators of NFκB is TNFα. TNFα is a pleiotropic cytokine that signals
through the TNFα receptor 1 (TNFR1). Upon TNFα binding, TNFR1 rapidly recruits
TNFR-associated death domain (TRADD). In turn, TRADD recruits Receptor Interacting
Protein 1(RIP1) (Hsu et al., 1996a) and TNFR associated factor 2 (TRAF2) (Hsu et al.,
1996b; Hsu et al., 1995) to the membrane. TRAF2 binds to the BIR1 domain of cIAPs
(Rothe et al., 1995; Samuel et al., 2006; Vince et al., 2009) and brings them into the
complex where cIAPs promote K-63 linked ubiquitination of RIP1 (Bertrand et al., 2011;
Bertrand et al., 2008). This complex of TRAF2/cIAPs/RIP1 is often referred to as
complex I. Ubiquitinated RIP1 interacts with both TAK1 and NEMO and serves as the
scaffold to bring NEMO and TAK1 in close proximity (Bertrand et al., 2008). TAK1
phosphorylates IKKα/β in their activation loops to activate their kinase activities and
drive nuclear translocation of NFκB transcription factors. In the absence of cIAPs, RIP1
associates with Fas associated death domain protein (FADD) and caspase-8, also
known as complex II, that leads to caspase-8 activation and apoptosis (Feoktistova et
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al.; Ikner and Ashkenazi; Park et al.). Caspase-8 can directly cleave the effector
caspase-3. Caspase-8 can also amplify the apoptotic signal through Bid cleavage and
Bax-mediated mitochondrial permeabilization (Li et al., 1998). NFκB can inhibit the
complex II and caspase-8 activation by increasing the transcription of cFLIP. cFLIP
competes with caspase-8 for FADD binding and prevents oligomerization-induced
activation of caspase-8 (Irmler et al., 1997; Krueger et al., 2001). In the absence of
cIAPs, RIP1 can also bind to RIP3 and induce caspase-independent cell death known
as necroptosis (Cho et al., 2009; Feoktistova et al.; Holler et al., 2000). While TNFα
primarily activates pro-survival signal through NFκB, TRAIL promotes complex II
formation and caspase-8 activation.
Cells also activate the pro-survival signals of NFκB in response to DNA damage
(Criswell et al., 2003; Huang et al., 2003; Li et al., 2001). Inhibition of NFκB promotes
apoptosis in cells with damage. However, DNA damage-induced NFκB activation does
not require assembly of a protein complex at the cell membrane but rather gets
activated in the nucleus, and is then transported to the cytoplasm. DNA DSBs activate
IKK through the formation of RIP1/NEMO/TAK1 complex without the requirement of
membrane receptors (Wu et al.; Yang et al.). However, a universal requirement of RIP1
for DNA DSB-induced NFκB activation has recently been debated (Hinz et al.; Wong et
al.). cIAP1 and cIAP2 play a critical and non-redundant role in the activation of NFκB in
response to DNA DSBs (Jin et al., 2009). While cIAP1 is required for monoubiquitination of NEMO, an essential step in NFκB activation, cIAP2 regulates a
downstream process (Feoktistova et al.; Jin et al., 2009).
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In this study, I demonstrated that loss of CHK2 activates NFκB in the early
stages of DNA damage and alters the ability of NFκB to promote the transcription of
pro-survival genes (cIAP2) rather than the transcription of pro-apoptotic genes (TNFα
and IL-8). I also demonstrated that CHK2 plays an essential in synergistic activation of
cell death in response to VP16 and TRAIL treatment through it ability to regulate cIAP2.
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3.3 Materials and Methods
Cell Culture and Treatments
HCT116 parent, HCT116 CHK2-/- and HCT116 p53-/- cells were obtained from The Core
Cell Center at Johns Hopkins University. HCT116 cells were maintained in McCoys 5A
medium (Life Technologies) supplemented with 10% FBS. MCF7 cells were maintained
in DMEM supplemented with 10% FBS and 1% L-Glutamine. In some cases cells with
treated with complete media containing the indicated concentration of VP16 (SigmaAldrich). For inhibition of NFκB, IKK inhibitors, BAY 11072 (Sigma-Aldrich) and BMS
35541 (Sigma-Aldrich), cells were treated with supplemented media to a final
concentration of 7.5 µM or 10 µM. For treatment with caspase 3 inhibitor, zDEVD-FMK
(BD Bioscience), caspase 8 inhibitor, zIETD-FMK (BD Bioscience), and RIP1 kinase
inhibitor, necrostatin 1 (Nec-1)(Sigma-Aldrich), cells were treated with complete media
containing respective amount of the inhibitor for four hours. Cells were then
supplemented with complete media containing DMSO or VP16 to a final concentration
of 25 µM. For blocking TNFα signaling, cells were incubated with complete media
containing VP16 alone or VP16 and TNF receptor soluble factor 1A (TNFRSF1A-Fc)
(R&D systems) for 48 h. In some cases, 24 h after VP16 treatment, cells were
supplemented with complete media containing TNFRSF1A-Fc to a final concentration of
10 µg/mL. For TRAIL-induced apoptosis, cells were grown in complete media
supplemented with 10µM VP16 for 48 h. Cells were supplemented with 100ng/mL
TRAIL (Milipore) for final 24 h.
Western blotting, Antibodies and Immunoprecipitation
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Cells were lysed in mammalian cell lysis buffer (MCLB (50 mM Tris HCl pH 8.0, 2 mM
DTT, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl,) supplemented with 1 mM microcystin
(Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), 2 mM PMSF (SigmaAldrich), protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail
(Calbiochem). Clarified lysates were resolved directly by SDS-PAGE and transferred to
nitrocellulose membranes for Western blotting. Membranes were blocked in TBST (20
mM Tris HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) containing 5% nonfat milk for 1 h
and incubated overnight in primary antibody diluted in TBST/5% nonfat milk.
Membranes were washed in TBST, incubated with HRP-conjugated secondary antibody
for 1 h in TBST/5% nonfat milk, and washed again in TBST. Membranes were
incubated with ECL (Pierce) and analyzed using a GelDoc Imaging System (BioRad).
Cleaved caspase -3, XIAP, and cIAP2 antibodies were from Cell Signaling. CHK2
antibody was from EMD Milipore. Actin and Tubulin were from Sigma-Aldrich. cIAP1
antibody was from R & D system. Endogeous cIAP2 in HCT116 and MCF7 cells was
detected using cIAP2 antibody from BD Biosciences and R&D system respectively. βcatenin antibody was from BD Biosciences, and GAPDH antibody was from Advanced
ImmunoChemical.
Transfections
HCT116 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. Briefly, HCT116 cells were plated at a density of 1.5 x 106
cells/6 cm dish. The next day, 2 - 2.5 µg of total plasmid was mixed with 500 µl of OptiMEM media in tube 1 and incubated at room temperature for 5 min. In tube 2, 6 - 7.5 µL
of Lipofectamine 2000 was mixed with 500 µL of Opti-MEM media and incubated at
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room temp for 5 min. After 5 min, tube 1 and tube 2 were mixed and incubated at room
temperature for 20 – 30 min. After the incubation, the transfection cocktail was added to
the plates containing 2 mL of complete media. 24 h post-transfection, the cells were
washed with 1X PBS and media was replaced. For RNAi transfections, Luciferase GL3
duplex and SMARTpool siRNAs specific to NEMO and RIP (ThermoScientific) were
transfected using DharmaFECT siRNA transfection reagent 2 (ThermoScientific).
Briefly, HCT116 cells were plated at a density of 0.3 x 106 cells/60mm dish for The next
day transfection. For transfection, 7.5 µl of 20 µM siRNA was mixed with 300 µl of OptiMEM media in tube 1, and 6 µl of Dharmafect 2 was mixed with 300 µl of Opti-MEM
media in tube 2. Both the tubes were incubated at the room temperature for 5 min.
Tube 1 was mixed with tube 2 and incubated for an additional 30 min. Meanwhile, the
media on the cells was replaced by 2.5 mL of complete media. Post-incubation, the
transfection cocktail was added to the cells in a dropwise manner. 24 h posttransfection, the media was replaced by 4 mLs of complete media.
Stable cell lines were generated by using lentivirus infection as described
previously (Stewart et al., 2003). Briefly, HEK293T cells were plated at 6 x 105 cells/6
cm dish the day before transfection. The next day, cells were transfected with a mixture
of 1 µg viral DNA encoding the gene of interest and 1 µg pHR’8.2deltaR packaging
plasmid at a ratio of 8:1 with pCMV-VSV-G envelope plasmid using Mirus LTR1
transfection reagent (Mirus). Target cells were plated at 1 x 106 cells/10 cm dish the
day before infection with the lentivirus. After HEK293T cells were transfected with viral
DNA for 48 h, target cells were infected in the presence of 10 µg/ml protamine sulfate
for 4 h. Virus was then removed and media was replaced. Infected cells were allowed
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to recover for 24 h and then were re-infected with lentivirus. Infected cells were
trypsinized and plated in media containing puromycin 48 h after the first infection with
lentivirus.
Cell Death and Caspase-3 Activity Assays
Cell Death was assessed using propidium iodide staining and fluorescent associated
cell sorting (FACS) as described previously (Lovly et al., 2008). For identifying Annexin
V and PI double positive cells, Annexin V : FITC Apoptosis Detection Kit I (BD
Biosciences) was used as per manufacturers protocol. Caspase-3 activity was
measured by utilizing the caspase-3 fluorogenic substrate Ac-DEVD-AFC (SantaCruz
Biotechnology). The cells were lysed in mammalian cell lysis buffer (MCLB: 50 mM Tris
HCl pH 8.0, 100 mM NaCl, 2 mM DTT, 5 mM EDTA, 0.5% NP-40) and incubated with 5
µg of the peptide at 37°C. The fluorescence was measured over time for a period of 150
min using FLUOstar Optima (BMG Labtech) and the data was analyzed using FLUOstar
version 1.30R3 (BMG Labtech).
NFκB activity luciferase assay
HCT116 cells were transiently transfected using Lipofectamine 2000 with 0.5 µg of
κB5→FLuc (ref) and 2µg of pRL-TK. Cells were allowed to recover overnight and then
plated in black-walled 96-well plates (Fischer Scientific). The next day, cells were
exposed to VP16 or vehicle (DMSO) for the specified durations and indicated
concentrations. Bioluminescence measurements were acquired in an IVIS 100 imaging
system using a final concentration of 150 µg/ml of D-Luciferin for firefly luciferase and
400 nM of coelenterazine for renilla luciferase.
Quantitative PCR
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Total RNA was isolated from the cells using RNeasy mini (Qiagen). 2 µg of total RNA
was reverse transcribed to synthesize cDNA using the SuperScript III First Strand
Synthesis kit (Invitrogen). Real time PCR was performed with TaqMan Gene Expression
Probe (Life Technologies) for cIAP1 ( Hs01112284_m1), cIAP2 (Hs00985031_g1),
TNFα (Hs01113624_g1), and IL-8 (Hs00174103_m1) using Bio-Rad CFX96 PCR
instrument (95°C for 10 min, then 40 cycles of 95°C for 30 s, 61°C for 1 min, and 74°C
for 1 min).
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3.4 Results
CHK2 inhibits NFκB-induced pro-survival signals
NFκB is known to promote cell survival in response to DNA damage and IAPs are
critical regulators of the NFκB pathway in response to a wide variety of stimuli.
Previously, we demonstrated that cIAPs provide anti-apoptotic activity in p53 proficient
cancer cells that are deficient in CHK2 (see Chapter 2). In this study we asked, if cIAPs
provided anti-apoptotic activity in CHK2 deficient cells through the regulation of the
NFκB pathway.
Proteosomal degradation of IκBα allows the NFκB dimers to translocate into the
nucleus and activate the transcription of their target genes (Beg et al., 1995; Henkel et
al., 1992). Thus, we monitored IκBα levels in VP16-treated HCT116 cells as a read out
for the activation of the NFκB pathway. CHK2-/- HCT116 contained lower levels of IκBα
protein at baseline compared with parental HCT116 cells (Fig. 3.1A, compare lanes 1
and 7) and IκBα was more quickly lost in CHK2 null cells following VP16 treatment (Fig.
3.1A). Interestingly, after VP16 treatment, the anti-apoptotic protein, cIAP2,
accumulated in CHK2-/- HCT116 cells (lanes 8-12) but not in parental cells (lanes 2-6).
On the other hand, in both parental and CHK2 null HCT116 cells, VP16 induced a
reduction in cIAP1 and XIAP levels in a dose-dependent manner (Fig. 3.1A).
Although IκBα levels fell in both parental and CHK2-/- HCT116 cells after 48 h of
VP16 treatment (Fig. 1A), quantitative RT-PCR revealed differential upregulation of
NFκB-target genes like TNFα, and cIAP2 in the two cell lines (Fig. 3.2B). Following
VP16 treatment, activation of pro-apoptotic genes like TNFα and IL-8 was much more
robust in parental compared with CHK2 null HCT116 cells (Fig. 3.2B). By contrast,
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activation of the anti-apoptotic cIAP2 gene was more robust in CHK2 null cells
compared to parental HCT116 cells (Fig. 3.2B). As noted earlier, a corresponding
increase in cIAP2 protein was also observed in VP16-treated CHK2-/- HCT116 cells
(Fig. 3.2A, lanes 7 – 12). Since it has been previously shown that early activation of
NFκB pathway has an anti-apoptotic role, while late activation of NFκB plays a proapoptotic role (Biton and Ashkenazi), we evaluated the NFκB pathway at earlier time
points after VP16 treatment. Interestingly, after VP16 treatment for 24 h, CHK2-/HCT116 cells had significantly lower levels of IκBα protein when compared to VP16
treated parental HCT116 cells (Fig. 3.2C). This indicated that NFκB pathway is
activated in CHK2-/- HCT116 cells earlier than in parental cells. To confirm this we
utilized a bioluminescence based NFκB reporter system described previously. The
reporter plasmid was transiently expressed in the cells followed by VP16 treatment.
Similar to IκBα levels, CHK2-/- HCT116 cells showed higher bioluminescence at basal
level when compared to parental HCT116 cells (Fig. 3.2D). Upon VP16 treatment,
bioluminescence in CHK2-/- HCT116 cells increased significantly more when compared
to the increase observed in parental cells. However, this difference was not observed
when cells were treated with higher concentration of VP16 (100 and 200µM). Similar
results were observed when bioluminescence was assessed after 12 h of VP16
treatment (Fig. 3.2E).
NFκB pathway does not contribute to VP16-induced apoptosis in HCT116 cells
Due to differential activation of NFκB target genes in VP16 treated parental and CHK2-/HCT116 cells, we assessed the role of NFκB in these cells. We pre-treated cells with
the IKK inhibitor, BAY 11072, to inhibit the NFκB pathway and then followed with VP16
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treatment (Fig. 3.2). 48 h of treatment with BAY 11072 induced significant death at
baseline in both parental and CHK2 null cells (Fig. 3.2A). Therefore, we incubated the
cells with two different IKK inhibitors, BAY 11072 (Fig. 3.2B, C and D) and BMS345541
(Fig. 3.3) for the final 24 h of the VP16 treatment. VP16 caused a reduction in IκBα
levels (Fig. 3.2B and Fig. 3.3A compare lane 1, 4, 7, and 10) and an increase in Ser532
phosphorylation of p65 subunit of NFκB dimer (marker for NFκB transcriptional
activation)(Fig. 3.3A) in both parental and CHK2-/- HCT116 cells. Pre-treatment with
BAY 11072 (Fig. 3.2B lanes 4 – 6 and 10 - 12) and BMS 345541 (Fig. 3.3B lanes 4-6
and 10-12) rescued IκBα levels in HCT116 cells in a dose dependent manner.
Consistent with our previous observation, VP16 induced cIAP2 accumulation in CHK2-/HCT116 (Fig. 3.2B, 3.3A compare lane 7 and 10). However, CHK2 null cells failed to
increase cIAP2 levels in the presence of either IKK inhibitors (Fig. 3.2B, Fig. 3.3A). This
suggested that following VP16 treatment, NFκB activation is required for cIAP2
upregulation in CHK2-/- HCT116 cells. Although inhibition of IKK reduced cIAP2
accumulation in CHK2 null HCT116 cells, it failed to alter the cleaved caspase 3 activity
(Fig. 3.2C, 3.3B) or apoptosis (Fig. 3.2D). However, BMS 354451 treatment marginally
increased apoptosis in both parental and CHK2-/- HCT116 cells. However, cell death
was still lower in CHK2 null cells compared to parental cells (Fig. 3.3C).
To inhibit the NFκB pathway throughout VP16 treatment, we transiently knocked down
key components of the pathway, including RIP1 (R1) or NEMO (N1), using a pool of 4
different siRNAs targeting their respective proteins. RIP1 (Fig. 3.4A, lanes 2, 5, 8, and
11) and NEMO (Fig. 3.4A. lanes 3, 6, 9, and 12) were both efficiently knocked down in
HCT116 cells. Knockdown of NEMO, but not RIP1, abolished the VP16-induced

157

reduction in the IκBα levels (Fig. 3.4A). This observation is consistent with a previous
report that RIP1 is dispensable for DNA-damage induced NFκB activation (Hinz et al.).
Loss of NEMO prevented the accumulation of cIAP2 in VP16 treated CHK2 nulls cells
(Fig. 3.4A, compare lanes 10 and 12). RIP1 loss had no impact on cIAP2 levels (Fig.
3.4A, lanes 9 and 10). This supports our earlier observation that the NFκB pathway is
required for VP16-induced upregulation of cIAP2 in CHK2-/- HCT116 cells. Knockdown
of RIP1 failed to alter apoptosis or cleaved caspase 3 activity in either parental or
CHK2-/- HCT116 cells (Fig. 3.4B, C). On the other hand, knockdown of NEMO reduced
the cleaved caspase 3 activity in both parental and CHK2-/- HCT116 cells with only a
small reduction in apoptosis of parental cells (Fig. 3.4B, C). However, apoptosis and
cleaved caspase 3 activity in CHK2 null cells remained lower compared to parental cells
even after NEMO loss. The results obtained with NEMO and RIP1 knockdown were
confirmed with individual siRNAs present in the pooled siRNA cocktail. All NEMO
specific siRNAs, with the exception of N2, were able to deplete NEMO resulting in
stabilization of IκBα (Fig. 3.5A lanes 3 – 6 and 9 – 12). Like the pooled siRNAs for
NEMO, individual siRNAs had almost no effect on apoptosis (Fig. 3.5B) but did result in
a reduction in cleaved caspase -3 activity in both parental and HCT116 cells (Fig. 3.5C).
On the other hand, individual siRNAs targeting RIP1 (R1-4) were each capable of
depleting RIP1 although to varying degrees. siRNA-R1 was the most efficient at
depleting RIP1 levels in vivo (Fig. 3.5D lanes 3 and 9). RIP1 knockdown had no effect
on apoptosis (Fig. 3.5E) or cleaved caspase 3 activity (Fig. 3.5F).

TNFα does not contribute to VP16-induced apoptosis in HCT116 cells
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Next we asked if upregulation of pro-apoptotic genes (TNFα and IL-8) played a role in
promoting apoptosis in VP16 treated parental HCT116 cells. Upon binding to its cell
surface receptors, TNFα promotes the formation of FADD, RIP1 and caspase-8
complex, also known as complex II. Additionally, in response to TNFα stimulation, RIP1
can associate with RIP3 to induce caspase-independent necrosis (Cho et al., 2009;
Feoktistova et al.; Holler et al., 2000). Thus, we treated HCT116 cells with a caspase-8
inhibitor (Casp8 in) and a RIP1 kinase inhibitor (Nec-1) alone or in combination and
monitored cleaved caspase 3 activity and cell death. As seen in Fig. 3.6, VP16 induced
cleaved caspase 3 activity, as well as apoptosis, in the HCT116 cells. CHK2 null cells
had lower caspase 3 activity and underwent less cell death when compared to parental
cells. Pre-treatment with caspase-3 inhibitor completely inhibited caspase-3 activity (Fig.
3.6A), but did not alter cell death in either parental or CHK2 null cells (Fig. 3.6B). Nec-1
decreased caspase-3 activity in both the parental and CHK2 null cells. Interestingly,
inhibition of caspase-8, both in the presence or absence of Nec-1, completely abolished
caspase 3 activity in parental and CHK2 null cells. This suggests that caspase-8 is
required for the activation of the effector caspase 3. Cell death, as measured by
annexin and PI double positive cells, decreased in parental cells in the presence of
caspase-8 inhibitor and Nec-1 alone and levels of cell death were not further decreased
when the two inhibitors were added together. Cell death in CHK2 null cells was
unaltered under identical experimental conditions.
Since, caspase-8 inhibitor was successful in inhibiting caspase-3 activation, we
wanted to test whether TNFα was responsible for cell death in the VP16 treated
parental cells. We were unable to detect any TNFα in the supernatant of cultures of

159

parental cells before or after VP16 treatment. This could be due to the fact that TNFα
levels were below the level of detection in the ELISA. To test this, we incubated cells
with soluble TNF receptor (TNFRS1) to prevent any TNFα that may have been in the
culture supernatant from signaling back into the cells. As seen in Fig. 3.7, treatment of
cells with TNFRS1 for 48 h (Fig. 3.7) or during the final 24 h prior to harvest (Fig. 3.7)
had no effect on IκBα or cIAP2 levels (panel A). Caspase-3 activity (panel B) and cell
death (panel C) were also unaltered under both conditions.
Taken together these results suggest that HCT116 cells do not secrete TNFα in
response to VP16 treatment. However, caspase-8 was required for caspase-3
activation.

CHK2 is required for synergistic effect of VP16 and TRAIL cell death
Our data demonstrated that CHK2 inhibits NFκB activity but this regulation is
dispensable for VP16-induced apoptosis. Therefore, we wanted to explore CHK2mediated regulation of NFκB in a different system. TRAIL is a member of the TNF
superfamily and induces apoptosis in various cancer cell lines. However, some cancer
cell lines are resistant to TRIAL but can be sensitized using chemotherapeutic agents
(Keane et al., 1999). It has previously been reported that HCT116 BAX-/- cells are
resistant to TRAIL but pre-treatment of these cells with VP16 can sensitize them to
TRAIL-mediated cell death (Wang and El-Deiry, 2003). Thus, we next tested the role of
CHK2 in VP16-induced sensitization of BAX null cells to TRAIL. We stably knocked
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down CHK2 in BAX null HCT116 cells and treated the cells with 10 µM VP16 for 24 h
followed by treatment with 100 ng/mL TRAIL for another 24 h (Fig. 3.8A). As seen in
Fig. 3.8, VP16 and TRAIL treatment alone failed to induce cleaved caspase-3 activity or
apoptosis (measured by sub-G1 DNA content) in BAX null HCT116 cells. However, pretreatment of BAX-null cells with VP16 significantly enhanced TRAIL-induced cleaved
caspase-3 activity (Fig. 3.8B) and apoptosis (Fig. 3.8C). Since, cIAP2 can provide antiapoptotic signals in response to TRAIL treatment, we monitored cIAP2 protein in BAX
null HCT116 cells after VP16 and TRAIL treatment. Interestingly, we observed
differential regulation of cIAP2 in the BAX null cells expressing control shRNA
compared with those expressing CHK2 shRNA. cIAP2 accumulated in both control and
CHK2 shRNA expressing cells that had been treated with TRAIL (Fig. 3.8A lanes 2 and
6). VP16 failed to significantly effect cIAP2 levels (Fig. 3.8A lanes 3 and 7). However,
pre-treatment with VP16, prevented TRAIL-induced accumulation of cIAP2 in BAX null
cells expressing GFP shRNA (Fig. 3.8A compared lanes 2 and 4) but not in cells
expressing CHK2 shRNA (Fig. 8A compared lanes 6 and 8).
Taken together these results suggest that CHK2 is essential for VP16-mediated
sensitization of cells to TRAIL-mediated cell death. In response to VP16 treatment,
CHK2 prevents TRAIL-induced cIAP2 upregulation and thereby promotes apoptotic
signals within the cells.
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3.5 Discussion
In response to various stimuli like, DNA damage, TNFα and TRAIL, cIAPs exert
their anti-apoptotic effects through the regulation of the NFκB pathway (Dai et al., 2009;
Hinz et al.; Jin et al., 2009; Mahoney et al., 2008b). cIAPs ubiquitinate several key
proteins in the NFκB pathway to promote its activation. In turn, cIAPs are themselves
transcriptional targets of NFκB dimers. This forms a positive feed-forward loop to
establish a strong pro-survival signal. Previously, we have shown that CHK2 inhibits the
anti-apoptotic signals of cIAP2 to promote chemotherapy-induced cell death in p53
proficient cell lines (refer chapter 2). In this study we demonstrated that CHK2 can
regulate the NFκB pathway and inhibit its early activation in response to VP16
treatment. However, CHK2 mediated regulation of NFκB was dispensable for VP16induced apoptosis. Furthermore, we have uncovered a potential role of CHK2 in the
extrinsic apoptotic pathway. We demonstrated that CHK2 is essential for VP16mediated sensitization of cells to TRAIL-mediated cell death.
Although NFκB is thought to primarily promote cell survival, some studies have
uncovered pro-apoptotic functions of NFκB as well. Recently, Biton et. al. (2011)
showed that DNA damage activates NFκB in two waves. In the initial stages of DNA
damage, NFκB provides anti-apoptotic signal and promotes cell survival. However,
upon prolonged exposure to DNA damage, cells secrete TNFα in a NFκB-dependent
manner to promote apoptosis. Similar to the observation made by Bitonet. al (2011), we
observed that in CHK2 null HCT116 cells, NFκB was activated at early stages of DNA
damage (12 and 24h) (Fig. 3.1C, D, E) and activated the anti-apoptotic gene, cIAP2
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(Fig. 3.1A, B). On the other hand, in parental cells, NFκB was activated at later stages
(48 h) and induced the transcription of the pro-apoptotic genes, TNFα and IL-6. Thus
we hypothesized that CHK2 prevents early activation of NFκB and drives the cells
towards cell death.
Although, loss of CHK2 altered the ability of NFκB to activate its pro-apoptotic
genes, inhibition of NFκB through two distinct IKK inhibitors, BAY-11072 and BMS345541, failed to rescue cell death or cleaved caspase activity in CHK2 null cells (Fig.
3.2, 3.3). Moreover, depletion of NEMO (Fig. 3.4, 3.5) was also not sufficient to increase
cell death in cells lacking CHK2. Surprisingly, NEMO knockdown reduced cleaved
caspase activity (Fig. 4B, 5C) in both the parental and CHK2 null cells. Similar
observations were made upon depletion of cIAP2 in HCT116 cells (Fig. 2.13).
Knockdown of NEMO reduced basal levels of cIAP2 protein in HCT116 cells, as well as
in VP16-induced levels in CHK2 null cells. It should be noted that loss of NEMO did not
completely remove cIAP2 protein from HCT116 cells. Inhibition of caspase-3 activity
was more prominent upon cIAP2 depletion compared with NEMO depletion. Thus,
decreases in caspase-3 activity in response to NEMO depletion might be driven, in part,
through reduction in cIAP2 levels. To our knowledge, a reduction in apoptosis in
response to cIAP2 loss has not been previously reported. We predict that this
observation may be a result of close association between cIAP1 and cIAP2. Under
normal conditions, cIAP1 targets cIAP2 for proteosomal degradation and loss of cIAP1
increases cellular levels of cIAP2 (Fig. 2.13). Thus cIAP2 might keep cIAP1 away from
its other substrates. Upon cIAP2 loss, a pool of cIAP1 that was earlier bound to cIAP2
might become available to inhibit apoptosis. In support of this hypothesis, concomitant
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loss of cIAP1 and cIAP2 does not impact cleaved caspase 3 activity in parental HCT116
cells (Chapter 2 Fig. 10). However, further experiments would be required to test this
hypothesis.
We observed that inhibition of caspase 8 suppressed caspase 3 activity in
HCT116 cells (Fig. 3.6). VP16 induced transcription of the NFκB target gene, TNFα
(Fig. 3.1). Since TNFα induces cell death through activation of caspase-8, inhibition of
NFκB through loss of NEMO might reduce TNFα release, and thereby reduce cell
death. However, we were unable to detect any TNFα in the supernatant of cultured
HCT116 cells and blocking of TNFα signaling did not affect cell death (Fig. 3.7). It has
been previously reported that although DNA damaging agents upregulate members of
TNFα superfamily, they do not contribute to caspase-8 activation or cell death (Milner et
al., 2002).
Although CHK2 mediated regulation of NFκB was dispensable for VP16-induced
apoptosis, we found that CHK2 was required for VP16-mediated sensitization of BAX
null cells to TRAIL. In resistant cells, TRAIL activates NFκB and upregulates cIAP2
expression (Kim et al.; Lin et al., 2000). Inhibition of NFκB or cIAP2 can sensitize
resistant cells to TRAIL treatment (Bockbrader et al., 2005; Franco et al., 2001; Jonsson
et al., 2003; Kim et al., 2002; Li et al., 2004; Seo et al.). VP16-treatment inhibited
TRAIL-induced cIAP2 levels and induced cell death. However, loss of CHK2 impaired
VP16-mediated inhibition of cIAP2 accumulation and reduced TRAIL-mediated cell
death. Thus, we hypothesized that VP16 activates CHK2, which in turn, can inhibit
NFκB and promote TRAIL-induced cell death.
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Overall, this study expands the role of CHK2 from the intrinsic apoptotic pathway
to the extrinsic apoptotic pathway by establishing its role in NFκB regulation. Since,
NFκB inhibition can increase the efficacy of various DNA damaging agents, CHK2
inhibitors might provide survival benefits for both cancer and normal cells. Therefore,
careful evaluation of the effects of CHK2 on the NFκB pathway would be key before
developing CHK2 inhibitors for clinical applications.
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Fig. 3.1 CHK2 inhibits VP16-induced early activation of NFκB
(A) Parental and CHK2-/- HCT116 cells were treated with VP16 at the indicated
concentrations for 48 h. Cell lysates were prepared and were subjected to Western
blotting with the indicated antibodies.
(B) Parental and CHK2-/- HCT116 cells were cultured in the presence of 25 µM VP16 for
48 h. Total RNA was isolated and was subjected to qPCR for the indicated genes.
(C) Parental and CHK2-/- HCT116 cells were treated with VP16 at the indicated
concentrations for 24 h. Cell lysates were prepared and were subjected to Western
blotting with the indicated antibodies.
(D, E) Parental and CHK2-/- HCT116 were transiently transfected with κB5-FLUC and
TK-RLUC reporter plasmids and treated with VP16 at the indicated concentrations for
24 h. Bioluminescence was then measured as described in Experimental Procedures.
The results in panels B, D and E are presented as mean (± s.e.m.) of three or more
independent experiments. *p<0.05, **p<0.005, ***p<0.0005, n.s. (not significant)
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Fig. 3.2. IKK inhibitor, BAY-11072, does not rescue cell death in CHK2 null cells
(A) Parental and CHK2-/- HCT116 cells were cultured in the presence of 5, 7.5 or 10 µM
Bay-11072 for 4 h followed by 25 µM VP16 for an additional 48 h. The Percentage of
cells containing sub-2N DNA content was assessed by PI staining followed by flow
cytometry.
(B, C, D) Parental and CHK2-/- HCT116 cells were cultured in the presence of 25 µM
VP16 for an additional 48 h. Cells were supplemented with 7.5 or 10 µM BAY-11072 for
the final 24 h. After 48h, cell lysates were prepared and were subjected to western
blotting (B) or assayed for cleaved caspase-3 activity (C). The percentage of cells
staining positive for annexin V and PI was assessed by flow cytometry (D).
The results in panels A, C and D are presented as mean (± s.e.m.) of three or more
independent experiments. ***p<0.0005, n.s. (not significant)
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Fig. 3.3 IKK inhibitor, BMS-345541, does not rescue cell death in CHK2 null cells
(A, B, C) Parental and CHK2-/- HCT116 cells were cultured in the presence of 25 µM
VP16 for an additional 48 h. Cells were supplemented with 7.5 or 10 µM BMS-345541
for the final 24 h. After 48h, cell lysates were prepared and were subjected to western
blotting (A) or assayed for cleaved caspase-3 activity (B). The percentage of cells
staining positive for annexin V and PI was assessed by flow cytometry (C).
The results in panels B and C are presented as mean (± s.e.m.) of three or more
independent experiments. ***p<0.0005, n.s. (not significant)
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Fig. 3.4 Knockdown of RIP1 and NEMO using pooled siRNA does not rescue cell
death in CHK2 null cells
(A, B, C) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control), RIP
siRNA (R1) or NEMO siRNA (N1) for 18 h were cultured in the presence of 25 µM VP16
for an additional 48 h. Cell lysates were prepared and subjected to Western blotting for
the indicated antibodies (A) or assayed for cleaved caspase-3 activity (B). The
percentage of cells staining positive for annexin V and PI was assessed by flow
cytometry (C).
The results in panels B and C are presented as mean (± s.e.m.) of three or more
independent experiments. ***p<0.0005, n.s. (not significant)
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Fig. 3.5 Knockdown of RIP1 and NEMO using individual siRNA does not rescue
cell death in CHK2 null cells
(A, B, C) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
individual NEMO (N1-4) siRNAs for 18 h were cultured in the presence of vehicle
(DMSO, -) or 25 µM VP16 (+) for an additional 48 h. Cell lysates were prepared and
subjected to Western blotting with the indicated antibodies (A). The percentage of cells
staining positive for annexin V and PI was assessed by flow cytometry (B). Cell lysates
were also assayed for cleaved-caspase 3 activity (C)

(D, E, F) Parental and CHK2-/- HCT116 cells transiently expressing GL3 (control) or
individual RIP1 (R1-4) siRNAs for 18 h were cultured in the presence of vehicle (DMSO,
-) or 25 µM VP16 (+) for an additional 48 h. Cell lysates were prepared and subjected to
Western blotting with the indicated antibodies (A). The percentage of cells staining
positive for annexin V and PI was assessed by flow cytometry (B). Cell lysates were
also assayed for cleaved-caspase 3 activity (C)
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Fig. 3.6 Caspase-8 is required for caspase-3 activation in VP16-treated HCT116
cells
(A, B) Parental and CHK2-/- HCT116 cells were cultured in the presence of 20µM
zIETD-FMK (Casp8 in), 30µM necostatin-1 (Nec-1), or 20µM zDEVD-FMK (Casp3 in)
for 4 h followed by 25 µM VP16 for an additional 48 h. Cell lysates were prepared and
assayed for cleaved caspase-3 activity (A). The percentage of cells staining positive for
annexin V and PI was assessed by flow cytometry (B).
The results in panels B and C are presented as mean (± s.e.m.) of three or more
independent experiments. *p<0.05, **p<0.005, ***p<0.0005, n.s. (not significant)
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Fig. 3.7 TNFα does not play a role in VP16-treated HCT116 cells
(A, B, C) Parental and CHK2-/- HCT116 cells were cultured in the presence of 10µg/mL
of TNFRSF1-Fc and 25 µM VP16 for. Cell lysates were prepared subjected to western
blotting for the indicated antibodies (A) and assayed for cleaved caspase-3 activity (B).
The percentage of cells staining positive for annexin V and PI was assessed by flow
cytometry (C).

(D, E, F) Parental and CHK2-/- HCT116 cells were cultured in the presence of 25 µM
VP16 for. Cells were supplemented with 10µg/mL of TNFRSF1-Fc for the final 24 h.
After 48 h, cell lysates were prepared subjected to western blotting for the indicated
antibodies (D) and assayed for cleaved caspase-3 activity (E). The percentage of cells
staining positive for annexin V and PI was assessed by flow cytometry (F).
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Fig. 3.8 CHK2 is required for VP16-induced sensitization to TRAIL
(A, B, C) HCT116 BAX-/- cells stably expressing control (GFP) shRNA or CHK2 shRNA
were treated with 10 µM VP16 for 48 h. Cells were supplemented with 100ng/mL TRAIL
for the final 24 h. Cell lysates were prepared and subjected to western blotting for the
indicated antibodies (A) or assayed for cleaved caspase 3 activity (B). The percentage
of cells containing sub-2N DNA content was assessed by PI staining followed by flow
cytometry (C)
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Chapter 4:
Summary, Discussion and Future Directions

188

4.1 Summary
The data presented in this dissertation provides further insight into the role of CHK2 in
DNA damage-induced apoptosis. Traditionally, it has been proposed that CHK2
promotes apoptosis through phosphorylation-mediated stabilization of p53. I have
provided evidence that CHK2 is dispensable for p53 regulation and transcriptional
activation of its target genes (p21, BAX, and PUMA). However, despite normal p53
activity, cells lacking CHK2 are impaired in their ability to undergo cell death. We have
identified cIAPs as novel CHK2 effectors that provide anti-apoptotic signals in the
absence of CHK2. CHK2 binds to Inhibitor of Apoptosis (IAP) family members, cIAP1
and cIAP2, but not XIAP, and potentially inhibits their activity to promote VP16-induced
cell death. I have further shown that CHK2 can inhibit the NFκB pathway potentially
through the regulation of cIAPs and plays an important role in the cellular response to
TNFα superfamily member, TRAIL. Overall, this work provides preliminary evidence that
CHK2 plays an important role in both extrinsic and intrinsic apoptosis pathway through
the inhibition of cIAPs.
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4.2 Discussion
4.2.1 Role of CHK2 in VP16-induced p53 stabilization and cell death
CHK2 plays a central role in the cellular response to DNA damage. DNA double strand
breaks activate CHK2 in an ATM-dependent manner (Ahn et al., 2002; Matsuoka et al.,
2000; Schwarz et al., 2003). In turn, CHK2 promotes cell cycle arrest and/or apoptosis
through regulation of numerous downstream effectors. One of the most widely studied
CHK2 effectors is the tumor suppressor protein, p53. CHK2 can phosphorylate p53 on
Ser20 and disrupt the interaction of p53 with its E3 ubiquitin ligase, MDM2 (Chehab et
al., 2000; Chehab et al., 1999). As a result, p53 is stabilized within the cell and induces
transcription of various genes involved in cell cycle arrest (p21) and apoptosis (BAX,
PUMA and NOXA). CHK2 null mice are protected from ionizing radiation-induced cell
death and fail to stabilize p53 and upregulate its transcriptional targets (Hirao et al.,
2000; Takai et al., 2002). This provided the first evidence that CHK2 is essential for p53
regulation and that it induces apoptosis through p53. However, subsequent studies in
various cancer cell lines have challenged this notion. Cancer cells are able to
phosphorylate p53 on Ser20, stabilize p53, and induce transcription of p53-targets even
in the absence of CHK2 (Ahn et al., 2003; Jallepalli et al., 2003). In support of these
studies, I have also shown that p53 regulation was intact in HCT116 and MCF7 cells
deficient in CHK2. In response to VP16, parental and CHK2 null HCT116 cells had
similar levels of total p53, pSer20 p53, and pSer15 p53. Despite normal regulation of
p53, both CHK2 deficient HCT116 and MCF7 cells underwent significantly less cell
death when compared with their CHK2 proficient counterparts. Interestingly, the
reduction in cell death decreased with increasing amount of damage. This suggests that
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at lower levels of damage, CHK2 is essential for cellular apoptosis, but is dispensable at
higher levels.
Taken together, our data, along with studies from different groups, have
demonstrated that CHK2 signals to the apoptotic machinery independent of its role in
p53 regulation. The goal of my thesis work was to identify additional CHK2 effectors that
are required for DNA damage induced cell death.

4.2.2 cIAPs inhibit VP16-induced apoptosis in the absence of CHK2
In order to identify the downstream effectors of CHK2 that play a key role in the
apoptotic pathway, we turned our attention towards the family of Inhibitor of Apoptosis
proteins (IAPs). IAP family members, especially cIAP1, cIAP2 and XIAP, are
endogenous inhibitors of cell death. We found that simultaneous inhibition of both cIAP1
and cIAP2 rescued VP16-induced apoptosis in cells lacking CHK2. On the other hand,
XIAP had no effect on cell death.
cIAPs are well-known regulators of cell death. They can bind and ubiquitinate the
effector caspase, caspase 3, and target it for proteosomal degradation (Choi et al.,
2009; Mica et al., 2004). On the other hand, cIAPs can also activate the NFκB pathway
in response to DNA damage and promote cell survival signals (Jin et al., 2009).
Inhibition of cIAPs can sensitize cells to various forms of DNA damaging agents (Gill et
al., 2009; Karasawa et al., 2009). This has prompted the development of several IAP
inhibitors, known as SMAC mimetics, for cancer treatment. One such SMAC mimetic,
BV6, is specific to cIAPs and can induce their rapid degradation (Blankenship et al.,
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2009; Varfolomeev et al., 2007). I demonsrated that BV6 increased apoptosis in CHK2
deficient cells to levels comparable to that measured in CHK2 proficient cells.
This result provided the first indication that cIAPs might provide anti-apoptotic
signals to prevent DNA damage-induced apoptosis in CHK2 deficient cells. Thus, we
conclude that CHK2 can promote DNA damage induced apoptosis through two distinct
pathways: a) by regulating p53 and promoting transcription of its pro-apoptotic targets
including BAX and PUMA, and b) by negatively regulating both cIAP1 and cIAP2 to
relieve their anti-apoptotic activities. However, it remains unclear how cIAPs provide
anti-apoptotic signals in the absence of CHK2. cIAPs can target cleaved caspases for
proteosomal degradation. Therefore, monitoring the ubiquitination status of effector
caspases in the presence and absence of CHK2 is expected to provide further insight
into the mechanism of cIAP-mediated inhibition of cell death.

4.2.3 CHK2 mediated regulation of cIAPs
To undersand mechanistically how CHK2 might regulate the cIAPs, we monitored for
interactions between CHK2 and cIAP1, cIAP2 and XIAP. We observed that both cIAP1
and cIAP2, but not XIAP, interacted with CHK2 when co-produced in HEK293T cells.
cIAPs are known E3 ubiquitin ligases that modify their substrates by attaching single or
multiple ubiquitin molecules. In addition to ubiquitination of other proteins, cIAPs can
also regulate their own cellular levels through auto-ubiqutiantion resulting in
proteosomal degradation (Dueber et al., 2011; Feltham et al., 2011; Mace et al., 2008).
CHK2 inhibited cIAP2 auto-ubiquitination in vitro in a phosphorylation dependent
manner. cIAPs are known to conjugate various forms of ubiquitin, K63- and K48-linked
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ubiquitin, and CHK2 was able to inhibit both forms auto-ubiquitination. Consistent with
this, CHK2 promoted cIAP2 accumulation by inhibiting cIAP2 turnover in the cells. As a
result, the cIAP2 half-life was extended from less than 15 min in the absence of CHK2
to more than an hour in the presence of CHK2. CHK2 mediated regulation of cIAP2
required its kinase activity as kinase-dead mutant of CHK2 had no effect on cIAP2
function. Although, cIAP1 and cIAP2 both interacted with CHK2, CHK2 promoted cIAP2
accumulation but not cIAP1 or XIAP accumulation.. cIAP1 is known to interact with
cIAP2 and induce its destruction (Silke et al., 2005). Thus, it is plausible that CHK2
inhibits cIAP1 indirectly through its interaction with cIAP2. Therefore, understanding the
effect of CHK2 on cIAP1 in the presence and absence of cIAP2 is key to understanding
how CHK2 regulates cIAP1.
Mass spectrometry of phosphorylated cIAP2 identified Thr35 as a CHK2
phosphorylation site in vitro. Thr35 of cIAP2 fall within the CHK2 consensus
phosphorylation motif (L X R X X S/T). Phosphorylation of cIAP2 on Thr35 increased
when it was co-produced with CHK2 in vivo. However, we found that CHK2 was
capable of regulating a mutant of cIAP2 that could not be phosphorylated on Thr35. In
addition, a mutant of cIAP2 lacking all four potential CHK2 phosphorylation sites (Ser81,
Thr145, and Thr261) was still stabilized in the presence of CHK2. Mass spectrometry
also identified Ser155 and Ser566 as CHK2 phosphorylation sites. Ser155 is present
within the BIR2 domain of cIAP2, and this domain is known to play a role in caspase
binding. Interestingly, Ser566 is present within the hydrophobic pocket of the RING
domain of cIAP1 and is conserved between cIAP1 and cIAP2. XIAP encodes alanine at
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the equivalent position. Current studies are aimed at determining if phosphorylation of
cIAP2 on Ser155 and Ser566 by CHK2 inhibits cIAP2 E3 ubiquitin ligase activity.

4.2.4 Role of CHK2 in regulation of the NFκB pathway
The NFκB pathway promotes cell survival in response to a wide variety of stimuli,
including DNA damage (Hinz et al., 2010; Huang et al., 2003b; Miyamoto, 2010; Wu et
al., 2006; Wu et al., 2010). cIAP1 and cIAP2 are required for NFκB activation and can
set a “feed-forward” activation loop that actively promotes cell survival (Bertrand et al.,
2011; Bertrand et al., 2008; Chu et al., 1997; Mahoney et al., 2008). Loss of CHK2 in
HCT116 cells results in the early activation of NFκB and upregulation of its pro-survival
target, cIAP2. On the other hand, in the presence of CHK2, NFκB was only activated at
later stages and induced the transcription of pro-apoptotic factors (TNFα and IL-8).
TNFα can activate cell death through the activation of caspase-8. Indeed, caspase 8 is
required for VP16-induced caspase-3 activity in HCT116 cells. Surprisingly, inhibition of
NFκB did not increase apoptosis in CHK2 null cells. Similarly, inhibition of TNFα
signaling did not inhibit cell death in the parental cells. However, loss of cIAP2 or NEMO
did reduce cell death in both parental and CHK2 null cells. Thus, NFκB might play a
more complex role in the VP16-treated parental and CHK2 null cells (Biton and
Ashkenazi, 2011; Huang et al., 2003a; Kasibhatla et al., 1998).
We demonstrated that CHK2 is required for VP16-induced sensitization of cells
to the apoptotic ligand, TRAIL. Activation of NFκB and its pro-survival target, cIAP2, has
been shown to promote TRAIL resistance (Franco et al., 2001; Keane et al., 2000; Kim
et al., 2002; Seo et al.). Thus, we hypothesize that CHK2 inhibits NFκB activation to
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promote TRAIL-induced apoptosis. Consistent with this hypothesis, VP16 is unable to
prevent TRAIL-induced cIAP2 accumulation in the absence of CHK2. Therefore, in
addition to its role in the intrinsic apoptosis pathway, CHK2 might also play an important
role in the death receptor-induced extrinsic apoptotic pathway.
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4.3 Future Directions
CHK2 inhibitors are currently being considered for cancer treatments. Numerous
studies have shown that CHK2 inhibitors can increase cell death in cell lines with nonfunctional p53 (Jiang et al., 2009; Jobson et al., 2009). This has been attributed to the
effects of CHK2 on cell cycle arrest. My thesis work has provided insight into a novel
p53-independent role of CHK2 in both the intrinsic and extrinsic apoptotic pathways. My
data suggests that inhibition of CHK2, even in p53 mutant cancers, might provide
survival benefit through the ability of cIAPs to inhibit apoptosis. Thus, understanding the
effects of CHK2 inhibitors on cIAPs and the NFκB pathway would be crucial before
considering their clinical application.
On the other hand, SMAC mimetics, like BV6, are currently being developed for
clinical application. It is believed that SMAC mimetics can enhance the efficacy of
chemotherapeutic agents. However, if CHK2 is able to efficiently inhibit cIAPs in
response to DNA damage, SMAC mimetics might not provide any therapeutic benefit.
As seen in my work, concomitant loss of cIAP1 and cIAP2 did not increase DNAdamage induced cell death in HCT116 and MCF7 cells. However, cIAP upregulation
(Bashyam et al., 2005; Dai et al., 2003; Gyrd-Hansen and Meier, 2010; Imoto et al.,
2001) and CHK2 downregulation (Bartkova et al., 2004; Sullivan et al., 2002; Tort et al.,
2002) is observed in various cancer subtypes. In such cancer subtypes, CHk2-mediated
cIAP inhibition might be suboptimal. Combination of SMAC mimetics with
chemotherapeutic agents that induce DNA double strand break might provide
therapeutic advantage in these cancer subtypes. Moreover, CHK2 is mutated in a
subset of patients with Li-Fraumeni syndrome, a familial cancer predisposition
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syndrome (Bell et al., 1999). Li-Fraumeni patients with CHK2 mutations have intact
TP53 gene and thus, can potentially benefit from combination of chemotherapy and
SMAC mimetic to relieve the cytoprotective effects of cIAPs in the absence of CHK2
function.
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